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iNORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET 
DET MEDISINSKE FAKULTET 
Linda Tømmerdal Roten 
Genetisk disposisjon for utvikling av svangerskapsforgiftning. 
Kandidatgenstudier i HUNT (Helseundersøkelsen i Nord-
Trøndelag) populasjonen. 
Svangerskapsforgiftning (preeklampsi) er en av de viktigste årsakene til sykdom og død hos 
gravide kvinner i den vestlige verden, og på verdensbasis fører tilstanden til at omkring 
63,000 kvinner dør per år. I Norge får omtrent 3% av alle gravide svangerskapsforgiftning.
Syndromet består av blodtrykksstigning og protein (eggehvite) i urinen, eventuelt med 
væskeansamling (ødem) i kroppen. Blodtrykkstigningen og proteinutskillelsen utvikler seg 
gjerne i siste halvdel av svangerskapet, det vil si etter svangerskapsuke 20. Alvorligheten av 
utslagene varierer, de kan være alt fra bagatellmessige med lett blodtrykksstigning og litt 
protein i urinen til en tilstand som truer liv. Svangerskapsforgiftning er en uforutsigbar 
sykdom, og i enkelte tilfeller kan situasjonen forverre seg meget raskt. Som oftest er det bare 
kvinnen som utvikler tegn på preeklampsi, men noen ganger vil også fosteret involveres. En 
dårlig utviklet morkake (placenta) kan føre til sviktende oksygen- og næringstilførsel, noe 
som kan resultere i veksthemning hos fosteret. Per i dag eksisterer det ingen effektiv 
behandling, og hvis de preeklamptiske manifestasjonene blir så alvorlige at de truer kvinnens 
liv, må svangerskapet avbrytes og fosteret forløses eller fødes uansett hvor kort svangerskapet 
har kommet. Dette innebærer at preeklampsi er en viktig årsak til prematur fødsel. Omtrent 
15% av alle premature fødsler er assosiert med svangerskapsforgiftning. 
Svangerskapsforgiftning kan være arvelig, og enkelte familier viser økt forekomst av 
sykdommen. Ved å studere slike familier fant man ut at arvestoffet/genene påvirker om man 
utvikler svangerskapsforgiftning eller ikke. Det er åpenbart at sykdomsutviklingen inkluderer 
genetiske mekanismer og risiko faktorer, men det er fortsatt uklart hvilke, hvordan de virker 
inn og hvordan de virker sammen med andre. Den genetiske komponenten ble først tilskrevet 
maternell arv, men det har siden vist seg at både mor og foster (via fars gener) bidrar til den 
genetiske risikoen for svangerskapsforgiftning. Men genetikken i svangerskapsforgiftning er 
kompleks og har de samme kjennetegnene som vanlige komplekse humane sykdommer som 
for eksempel hjerte-kar sykdommer og diabetes. Disse sykdommene kjennetegnes ved at det 
ikke er noe entydig og klart arvemønster, og at det er effekten av mange gener, i kombinasjon 
med livsstil og miljøfaktorer, som bidrar til risiko.  
Hel-genom skanning (koblingsanalyser) har blitt brukt til å kartlegge genetiske områder som 
predisponerer for sykdom i familier med økt forekomst av svangerskapsforgiftning. Slike 
familier har mest sannsynlig en sterk genetisk predisposisjon. I tillegg er slektninger veldig 
like i det genetiske materialet (DNA), dette gjør det enklere å lete etter områder som er koblet 
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til sykdom når man sammenligner syke og friske individer. Men selv om slike familiestudier 
har vært en suksess når det gjelder å finne kromosomområder som er koblet til sykdom, har 
det vist seg at å identifisere gener som predisponerer for svangerskapsforgiftning er vanskelig. 
Dette er derfor fortsatt en av de mest fundamentale og viktige utfordringene innen 
fødselsmedisin (obstetrikk).  
Arbeidet som presenteres i denne avhandlingen har hatt som mål å identifisere gener hos mor 
som predisponerer for svangerskapsforgiftning innenfor kromosomområder som har blitt vist 
å være koblet til sykdommen (2q, 5q, 13q). Grunnlaget for at det har vært mulig å 
gjennomføre dette prosjektet er den andre store helseundersøkelsen i Nord-Trøndelag 
(HUNT2), der det ble samlet inn blodprøver fra alle deltagerne. Ved å sammenligne 
arvestoffet (DNA) fra kvinner som har hatt svangerskapsforgiftning (n=1.139) med kvinner 
som ikke har hatt svangerskapsforgiftning (2.269) har vi klart å finne gener (SEPS1, ACVR2A, 
ERAP1, ERAP2, CRHBP, TNFSF13B) som sannsynligvis er viktige for utvikling av 
sykdommen. Felles for disse genene er at de er viktige for at forholdet mellom mor og foster 
skal være bra under svangerskapet. Disse genene er viktige for at morkaken og blodårene 
mellom mor og morkaken skal utvikle seg normalt, eller for at mors immunsystem skal 
akseptere fosteret (som for mor oppleves som delvis ukjent på grunn av at halve arveanlegget 
er fra far). Noen av disse genene (SEPS1, ACVR2A) er også kjent å være involvert i andre 
sykdommer, som også er assosiert med svangerskapsforgiftning. Hjerte-kar sykdom er for 
eksempel mer hyppig blant kvinner som har hatt svangerskapsforgiftning, og noen av risiko 
faktorene og mekanismene som er involvert i sykdomsutviklingen er felles for disse to 
sykdommene. Også såkalte metabolske tilstander, med forstyrrelser i karendotel, sukker- og 
fett-omsetning, er mer vanlig blant kvinner som har hatt svangerskapsforgiftning. Det er 
derfor sannsynlig at kunnskapen om gener/genetiske mekanismer som er viktige i 
svangerskapsforgiftning også vil kunne gi relevant innsikt når det gjelder å forstå utvikling av 
hjerte-kar sykdom. 
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SUMMARY
Preeclampsia is a major cause of maternal morbidity and mortality in the western world, and 
approximately 63,000 women dye yearly of the disease worldwide. This disorder is 
characterized by increased maternal blood pressure (hypertension) and proteinuria, sometimes 
also with edema. The clinical manifestations develop during the latter half of the pregnancy. 
However, preeclampsia is a condition which may aggravate very quickly, from minor (mild 
hypertension and traces of protein in the urine) to life-threatening manifestations. Generally, 
preeclampsia manifestations are maternal, but sometimes the fetus is also involved. The most 
important fetal sign is growth restriction, due to an insufficiently developed placenta and 
reduced supply of oxygen and nutrition. Unfortunately, women who develop preeclampsia 
have an increased risk of loosing their baby prior to, during or immediately after birth. 
Preeclampsia lacks an effective prevention strategy or curative treatment, and if the 
preeclamptic manifestations threaten maternal or fetal life, the only alternative is to deliver 
the baby and placenta, irrespective of gestational age. This implies preeclampsia as one of the 
most important causes of premature delivery.  
Preeclampsia may be heritable, and some families show an increased occurrence of the 
disease. By studying such families, it was discovered that development of preeclampsia is 
influenced by the genetic material/genes. Genetic mechanisms and risk factors are obviously 
included in development of this disease, however it is still unclear which, what their influence 
is and how they work together with other mechanisms or risk factors. The genetic component 
was initially ascribed to maternal inheritance, but it has later turned out that both mother and 
fetus (via paternal genes) contribute to the genetic risk of developing preeclampsia. But the 
genetics of preeclampsia are complex and shares characteristics of common complex diseases 
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such as cardiovascular diseases and diabetes. These diseases are characterized by no clear-cut 
and distinct pattern of inheritance, and it is the effect of many genes in combination with 
lifestyle and environmental factors that contribute to the risk. 
Whole genome scans (linkage analyses) have been used to map genetic loci that predispose to 
disease in families with increased occurrence of preeclampsia. These families are likely to 
have a strong genetic predisposition. In addition, it is easier to search for regions in linkage 
with disease by comparing affected and unaffected individuals that are related since relatives 
are very much alike genetically (in their DNA). Although these family studies have been 
successful in identifying chromosomal regions in linkage with disease, it has proven difficult 
to identify the actual genes predisposing to preeclampsia. Thus, this is still one of the 
fundamental and important challenges in obstetrics. 
11 INTRODUCTION
1.1 Preeclampsia – maternal characteristics 
Preeclampsia is a pregnancy specific disorder affecting approximately 3-5% of all pregnant 
women in the western world,1 exhibiting substantial maternal and fetal morbidity and 
mortality.2 The world-wide prevalence of preeclampsia is estimated to be as high as 8%, 
although this rate is higher in developing countries3 and amongst selected ethnic ancestry4.
Approximately 63,000 women dye yearly of preeclampsia worldwide.5 Preeclampsia typically 
develops in the latter half of pregnancy (after 20 weeks of gestational age), and is particularly 
prominent at the end of the pregnancy. The maternal preeclamptic syndrome is characterized 
by increased blood pressure (BP) (development of hypertension) and protein in the urine 
(proteinuria), and edema of the extremities is often witnessed together with these 
manifestations. Preeclampsia is an unpredictable disease, which may progress very rapidly 
and result in extremely high levels of maternal BP, convulsions and visual changes, 
potentially leading to organ and systemic failure. This final and very severe phase of 
preeclampsia denotes eclampsia. Women with eclampsia often have seizures, can fall into a 
coma, or at worst case the death of the mother and/or the baby. Eclampsia may occur before, 
during or immediately after birth, and the condition often leads to changes in the circulatory 
system and kidney failure, together with heart and lung failure.
1.2 Preeclampsia – fetal problems 
The function of the placenta is affected by preeclampsia, causing reduced blood flow and 
thereby lack of oxygen and nutrition to the fetus. Normally this is not life-threatening for the 
fetus but may lead to growth restriction. Unfortunately, preeclampsia sometimes causes death 
2of the baby. Women experiencing preeclampsia have an increased risk (odds ratio 1.5) of 
loosing their baby before, during or shortly after birth.6 Another aspect is the fact that delivery 
of the baby and placenta is the only effective ‘treatment’ if the life of the pregnant woman is 
threatened, irrespective of gestational age. Therefore, preeclampsia is an important cause of 
premature birth, and more than 15% of all premature births in Norway have been shown to be 
associated with preeclampsia.6 If preterm intervention is required by cesarean section (CS), 
promotion of short- and long-term complications from prematurity for the new-born baby 
(neonate) is evident. 
1.3 Preeclampsia – an important health problem 
Pregnancy may be considered a maternal stress test, and the physiologic demands of 
pregnancy can predict a woman’s health in later life and reveal risk of chronic diseases. 
Preeclampsia has been associated with an increased risk of developing metabolic syndrome 
later in life.7-10 Metabolic syndrome refers to a group of conditions including hypertension, 
high blood levels of glucose and triglycerides, low levels of high density lipoprotein (HDL), 
too much fat around the waist, associated with increased risk of impaired glucose tolerance, 
type 2 diabetes, hypertension, dyslipidemia, obesity and heart disease.11,12 The exaggerated 
responses reflective of the metabolic syndrome often seen in preeclampsia may herald future 
cardiovascular and metabolic disease risk(s).13 In the HUNT population it appears that 
preexisting metabolic syndrome may predispose to preeclampsia.14 Elevated levels of 
triglycerides, cholesterol, low density lipoprotein cholesterol, non-high density lipoprotein 
cholesterol and BP in women who later developed preeclampsia was observed,14 in 
accordance with observations reported by others.15,16 Women experiencing preeclampsia seem 
to be predisposed to cardiovascular disease (CVD) and vice versa, cardiovascular risk factors 
appear to predispose to developing preeclampsia. Could metabolic syndrome possibly be an 
3intermediate state between preeclampsia and CVD? Meaning that preeclampsia is an early 
manifestation in development of CVD? 
Several studies have shown, and it is now widely accepted, that women with a history of 
preeclampsia have an increased risk of developing CVD later in life (reviewed by Harskamp 
et al.17). Examples of remote CVDs are hypertension, myocardial infarction, ischemic heart 
disease, and stroke. Women with severe preeclampsia and preterm delivery and those with 
recurrent preeclampsia seem to be at greater risk,18-20 but even preeclampsia that occurs in the 
first pregnancy at term and never recurs is associated with increased later life CVD.19 A study 
of data from the Medical Birth Registry of Norway (MBRN) show that the risk of death from 
cardiovascular causes among women with preeclampsia and a preterm delivery was about 8-
fold higher than among women having normal pregnancies.20 In general, patients with a 
history of preeclampsia seem to have higher risk of all-cause death19,20 and significant 
increase of mortality from coronary heart disease (CHD) has been reported.20-25 An increased 
risk of morbidity and mortality from ischemic stroke in women with a history of preeclampsia 
has also been reported.26,27 These findings do not imply that every preeclampsia survivor is 
destined to develop CVD, but rather, a history of preeclampsia may identify a population at 
significantly increased risk for CVD. Whether this increased risk of CVD is due to underlying 
conditions that predispose women to both conditions or due to long-term sequelae of the 
preeclampsia syndrome is unknown.  
Studies of long-term effects of preeclampsia on maternal BP have demonstrated that 
preeclamptic women are at increased risk of chronic hypertension.28-30 For most women with 
a history of preeclampsia, BP regresses to normal after delivery. However compared with 
women who have experienced only normal pregnancies they have higher BPs.31 BP regulation 
4and the kidney are closely linked, and renal function is altered with the dramatic hormonal 
and hemodynamic changes of pregnancy. Kidney disease has been suggested to be a likely 
long-term effect of preeclampsia. A Norwegian study reporting that preeclamptic women had 
a substantially increased risk for having a later kidney biopsy supported this hypothesis.32
Recently the same research group linked data from the MBRN and the Norwegian Renal 
Registry and concluded that preeclamptic women do have an increased risk of end-state renal 
disease.33
1.4 Definition of preeclampsia 
Hypertension is considered to be the hallmark of preeclampsia by all existing classification 
systems, while proteinuria may be a late manifestation of preeclampsia. Although this disease 
has been known for a very long time, there is currently no international consensus on 
definition or diagnostic criteria of preeclampsia. There is a wide diversity of definitions and 
diagnostic criteria for preeclampsia34,35 and these have also changed over time. Pregnancy-
induced hypertension (PIH) could signify both gestational hypertension and preeclampsia to 
some, whereas others require PIH plus proteinuria to signify preeclampsia. Previous 
definitions included edema, however, since it occurs in many women with normal 
pregnancies it is not a suited discriminant. Thus, many classification schemes have abandoned 
edema as a marker for preeclampsia.36-38 Although most define preeclampsia as a combination 
of hypertension and significant proteinuria today, there have been and probably still are 
inconsistencies in the definitions of hypertension and proteinuria. There seems to be an 
agreement to use absolute BP thresholds of 140 mmHg (systolic BP, SBP) and/or 90 mmHg 
(diastolic BP, DBP) to define hypertension in pregnancy.39,40 Previously, an increase of DBP 
(15 mmHg) and/or SBP (30 mmHg) was also included in the diagnostic criteria and even 
5these increments in BP alone have been sufficient to define hypertension in pregnancy, even 
when the absolutes value remained below 140/90 mmHg.40
The methods/techniques (and instruments) used to perform the BP measurements probably 
vary significantly. This is a problem since this may lead to quite different BP readings.35,41-43
It is recommended that gestational BP elevation should be defined on basis of at least two 
determinations, since measuring the BP successively may result in different readings. 
However, the measurements of increased BP should be no more than a week apart.40 The 5th
Korotkoff has been established as the sound closest to true diastolic pressure,37,44,45 and it is 
recommended used,45,46 also in Norway.47,48
A level of 0.3 g/L in a 24 hour urine sample has frequently been used for “significant” 
proteinuria, but also in measuring proteinuria there are different methods available. A 
qualitative 1+ dipstick reading usually correlates with 0.3 g/L in a random urine 
determination with no evidence of urinary tract infection, and is also used to define significant 
proteinuria. The standard practice of collecting 24 hour urine specimen for protein is time 
consuming, inconvenient and cumbersome, especially for patients who are not hospitalized. 
The urinary dipstick giving a qualitative result has been shown to be a poor predictor of 24 
hour urine total protein level.49-51 A dipstick value is less useful since a 1+ reading can 
produce many false positives and false negative results.39,40 It is therefore recommended that 
the diagnosis be based on a 24 hour urine sample if possible. More recently, the use of a 
protein/creatinine ratio (0.3) has been suggested as an alternative to the standard practice of 
collecting a 24 hour urine for protein.52-54 The accuracy of this test is still being investigated. 
6There is no doubt that an international consensus of both definition and diagnosis criteria of 
preeclampsia together with the use of identical methods to measure BP and proteinuria, would 
make comparisons between studies much easier to interpret. Table 1 summarizes the 
commonly used diagnostic criteria for hypertension and preeclampsia.  
Table 1: Commonly used diagnostic criteria for hypertension and preeclampsia. 
Hypertension SBP 140 mmHg and/or DBP 90 mmHg  
Preeclampsia Hypertension and significant proteinuria;  
0.3 g/L in a 24 hour urine sample, or 1+ on a qualitative dipstick reading 
Attempts to categorize preeclampsia as mild or severe have also been made.40,55 Severe 
preeclampsia is often defined on basis of BP levels of 110 mmHg diastolic and 160 mmHg 
systolic, severe proteinuria (defined as >3 g/ 24 hours), sudden oliguria, neurologic symptoms 
such as headache, laboratory tests demonstrating thrombocytopenia (defined as <100,000 per 
μL), hemolysis, abnormal liver function.55,56 Efforts to recognize different subsets of women 
with preeclampsia, based on criteria such as gestational age at delivery and association with 
intrauterine growth restriction (IUGR), have also been made. Early onset preeclampsia, i.e. 
onset before 34 weeks of gestation, has been associated with greater morbidity than late onset 
preeclampsia presented at term. 
1.4.1 Preeclampsia in Norway 
The Norwegian Society of Gynecology and Obstetrics 
The diagnostic criteria for preeclampsia in Norway are set by The Norwegian Society of 
Gynecology and Obstetrics (NGF). The first written national (Norwegian) guidelines to 
clinicians diagnosing pregnant women were introduced in 1995.57 Before 1995 international 
7classification of disease (ICD) codes were used to define preeclampsia. ICD-8 codes were 
available from 1965,58 but were generally not used until 1969 in Norway.59 Relevant ICD-8 
codes are 637.0 Preeclampsia, 637.1 Eclampsia and 637.9 Toxemia, unspecified. In 1986 
clinicians started to use ICD-9 codes59,60 to define preeclampsia and used these codes until the 
NGF guidelines were introduced in 1995. The following ICD-9 codes were used to define 
preeclampsia 642.4 Mild or unspecified preeclampsia and 642.5 Severe preeclampsia. The 
Norwegian version of the ICD-9 code 642.2 was Hypertension in pregnancy, intrapartum or 
postpartum, not previously diagnosed, with albuminuria, edema or both – specified as mild or 
unspecified, while ICD-9 642.5 was Increased blood pressure in pregnancy, intrapartum or 
postpartum, not previously diagnosed, with albuminuria, edema or both – specified as severe. 
Since there were no written national guidelines before 1995, it is difficult to determine what 
diagnostic criteria were used before 1995. In the NGF guidelines from 1995 the diagnostic 
criteria for preeclampsia were 1) blood pressure t140/90 mmHg or an increase of diastolic 
blood pressure t15 mmHg compared with mean blood pressure values measured before 20 
weeks of gestation and 2) proteinuria with t0.3 g/L in a 24 hour urine sample or t1+ on a 
dipstick reading after 20 weeks of gestation.57 In the revised NGF guidelines published in 
1998 the criteria for the BP changed to increased BP t140/90 mmHg measured at least two 
times, while the criteria for proteinuria remained the same.61 The 1998 guidelines were used 
until new guidelines were introduced in 2006.62 The criteria for mild preeclampsia in the 
guidelines from 2006 were 1) blood pressure t140/90 mmHg combined with 2) proteinuria 
t0.3 g/L in a 24 hour urine sample or a t1+ on a dipstick reading measured on at least two 
occasions with a 4-6 hour interval. The guidelines from 2006 also specified the following 
diagnostic criteria for severe preeclampsia by (one or more of the following manifestations) 
blood pressure t160/110 mmHg, proteinuria t3 g/L in a 24 hour urine sample, concentrated 
urine with oliguria (<500 mL/24 hours) or increased serum creatinine, thrombocytopenia 
8(<100 x 10*9/L) or signs of microangiopathic hemolytic anemia, increased levels of liver 
enzymes, severe epigastric pain, nausea and vomiting, severe headache and other 
cerebral/visual disturbances, pulmonary edema, cyanosis. The diagnostic criteria for 
preeclampsia in the 2006 guidelines (with at least two blood pressure and proteinuria 
measurements required) were unaltered in the latest release of NGF guidelines in 2008,63
which to this day (April 2009) remain the guidelines used to diagnose preeclampsia among 
medical doctors in Norway. 
1.4.2 Preeclampsia in the HUNT case/control cohort 
Preeclampsia in our Norwegian HUNT case/control cohort was defined according to the 
criteria given by National High Blood Pressure Education Program Working Group on High 
Blood Pressure in Pregnancy.40 Preeclampsia was defined as the onset of persistent 
hypertension (BP 140/90 mmHg) in combination with proteinuria (0.3 g/L in a 24 hour 
urine sample or a 1+ on an urine dipstick reading) after the 20th week of gestation. 
1.5 Etiology and pathogenesis of preeclampsia 
Preeclampsia is a disorder of numerous etiological hypotheses pertaining to immunological, 
vascular, ischemic and inflammatory biological mechanisms with genetic susceptibility and 
environmental risk factors (reviewed in 64-66). The etiology of preeclampsia is likely to be a 
combination of all of these factors. Known risk factors for preeclampsia (reviewed in ref 67)
include: 1) maternal factors, such as primiparity, previous preeclamptic pregnancy, multiple 
pregnancies (e.g. twins), obesity, and pre-existing medical conditions such as chronic 
hypertension, diabetes, renal disease, autoimmune disease and antiphospholipid syndrome, 
and maternal age,1,68 2) family history of preeclampsia and 3) ethnicity. The time between 
9pregnancies and change of partner have also been suggested to associate with an increased 
risk for developing preeclampsia.69-71 It is also evident that interactions between the mother 
and the fetus via the placenta and decidua are important.  
Whilst the clinical gestational hypertensive and proteinuric manifestations usually present 
themselves after 20 weeks gestation, the mechanisms underlying these manifestations are 
likely to occur at much earlier gestational age. This dichotomy of pathophysiological events 
has therefore been proposed to represent a two-stage process; with poor placental perfusion 
(Stage 1) leading to the maternal responses evoked with varying degrees of clinical 
manifestations (Stage 2).72 It has been known for nearly 100 years that preeclampsia is 
probably a placental condition.73,74 Preeclampsia only develops if a placenta is present, i.e. the 
starting point is postulated to derive from the placenta.75 Therefore, a central role of the 
placenta in the pathogenesis of this disease is undisputed. Poor placentation is a powerful 
predisposing factor, usually leading to the maternal syndrome of preeclampsia. But, although 
reduced placental perfusion seems required for development of preeclampsia, it is obviously 
not sufficient when exploring the linkage between reduced placental perfusion and the 
maternal systemic manifestations. Recently, the Two Stage Model has been modified (Figure 
1a),76 based on the hypothesis that abnormal implantation/placentation occurs before 
abnormal vascular remodeling of spiral arteries.77 In addition, it is suggested that maternal 
constitutional factors (genetic, behavioral or environmental) may play a more extensive role 
than previously thought. Development of preeclampsia seems to depend on an interaction 
between the reduced perfusion and maternal genetic predisposition.78 It is likely that there are 
several factors, which may differ in different women, serving as linkers between the two 
stages (Figure 1b).76 Until recently the linking factor(s) has been considered as a pathogen or 
toxin, however, factor(s) modifying maternal metabolism to increase nutrient availability and 
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acting on the placenta to facilitate nutrient transfer is another possibility.76 Whilst there is 
epidemiological evidence suggesting a paternal (fetal) contribution,70 it is unknown what role 
fetal genes may play. 
The theories on the cause of preeclampsia are often depicted from two different views, a 
vascularist’s or an immunologist’s. However, one should bear in mind that there is no clear 
distinction between vascular and immune events since most, if not all, cytokines secreted 
within the immune system have pleiotropic properties.79
1.5.1 The vascular view
In a normal pregnancy invading cytotrophoblasts displace vascular endothelial cells in the 
uterine spiral arteries by replacing muscular and elastic components with a fibrinoid layer, 
resulting in high capacity, low resistance tubes unresponsive to vasoreactive stimuli. Poor 
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placentation, revealed as insufficient cytotrophoblast invasion and defective remodeling of 
maternal spiral arteries, is a widely recognized predisposing factor for preeclampsia. 
Insufficient uteroplacental circulation leading to hypoxia, oxidative stress and, in most severe 
cases, infarction may be the result.80,81 However, there are different views as to how this 
arises. One view is that the inadequate remodeling of the spiral arteries during placentation 
results in reduced blood flow,82 which implicates chronic hypoxia in the placenta.83 A second 
view is that the volume flow is normal, but ischemia reperfusion is created because of 
intermittent blood flow through narrow spiral arteries that retain their smooth muscle.84
Subsequently, oxidative stress and reactive oxygen species (ROS) result from variable 
oxygenation in the intervillous space because of the intermittent high velocity flow.83
Whatever mechanism at play, the end result would be placental oxidative stress and 
dysfunction. Reduced placental perfusion has been confirmed by Doppler ultrasound 
assessment of blood flow velocities in the uterine arteries which have indicated an increased 
incidence of patterns associated with high resistance.85,86 Recently it was proposed that the 
primary placental problem generating the preeclampsia syndrome is likely to be oxidative 
stress rather than hypoxia.83,84 It has now become widely accepted that the insufficient utero-
placental oxygenation in preeclampsia results in placental secretion of soluble factors into the 
maternal system inducing maternal endothelial cell dysfunction and the clinical features of 
preeclampsia.87
The systemic inflammation that is commonly evident in all pregnancies is often exacerbated 
in a preeclamptic pregnancy.64,75 Therefore the clinical features of preeclampsia always 
overlap with those of normal pregnancy. Inflammation is an attempt by the body to restore 
and maintain homeostasis after injury and is an integral part of the body defense, involving 
the vascular system of the body. In the late 1980s and early 1990s it became apparent that 
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preeclampsia, in common with many other vascular disorders, was a state of endothelial cell 
activation.88 This endothelial cell activation appears to be part of a generalized intravascular 
inflammatory response involving maternal leukocytes, the coagulation and complement 
systems.64 However, the origin of endothelial dysfunction in preeclampsia is still unknown, 
and it is likely to be diverse. The link between abnormalities in trophoblast invasion and 
generalized maternal endothelial dysfunction seen in preeclampsia may be via release of 
placental factors.75
Trophoblast microparticles 
The placenta undergoes a continuous process of growth and apoptotic events in which 
numerous microparticles are produced. Microparticles are cellular, membrane-bound vesicles 
that mediate cell-to-cell communication with many potential roles in a number of biological 
processes such as inflammation, angiogenesis, hemostasis, and thrombosis.89 In conditions 
associated with enhanced systemic inflammation, the levels of circulating microparticles are 
increased.90,91 This is the case in the third trimester of a normal pregnancy, and to a greater 
degree in preeclamptic pregnancies.92-97 Particularly syncytiotrophoblast microparticles 
(STBM), which form the maternal-placental interface, are suggested to directly damage 
endothelial cells and also to stimulate systemic inflammatory responses.98 Several other 
factors, including leukocyte and platelet membrane particles, ROS, activated neutrophils, 
cytokines, growth factors, angiogenic factors and hormones are also released during the 
apoptotic cascade. These factors will then interact with maternal vascular endothelium which 
may already be damaged. 
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Oxidative stress 
The placenta is the essential interface between maternal circulation carrying oxygen rich 
blood and the fetal circulation. In early pregnancy the outermost tissue of the conceptus, 
mainly placental syncytiotrophoblasts, contains very low antioxidant enzymes, making these 
cells particularly sensitive when exposed to the highest concentrations of oxygen coming 
from the maternal circulation. Pregnancy is therefore a state of oxidative stress arising from 
increased maternal metabolism and the metabolic activity of the placenta. Oxidative stress is 
suggested to arise from an overproduction of ROS, which exceeds the capacity of the 
antioxidant defences, due to hypoxia re-oxygenation (H/R) injury. There is strong evidence 
that preeclampsia is a state of excessive oxidative stress (reviewed in 84), which may cause 
endothelial dysfunction.99 Considering the unique role of the placenta, it is likely that this 
organ is the origin or major source of oxidative stress observed in preeclampsia.100 Placental 
hypoxia and re-oxygenation may also stimulate placental synthesis of cytokines e.g. TNF-
Į,101 and could lead to lipid peroxidation. Lipid peroxides bind to lipoproteins and are thereby 
transported to distant sites in the body where they may cause damage and result in systemic 
oxidative stress. Increased lipid peroxidation has been reported in preeclampsia.102-106 Many 
triggers of placental oxidative stress have been suggested, including high concentrations of 
plasma endothelin-1,107 increased superoxide generation via the enzyme NADPH oxidase,108-
110 lower levels of superoxide dismutase (SOD)105,111 and glucose 6-phosphate-
dehydrogease111, lower activity of Cu/ZnSOD and glutathione peroxidase and lower levels of 
vitamin E.112 Several markers of oxidative stress, such as malondialdehyde (MAD) and 
isoprostane 8-iso-PGF-2Į are elevated in preeclampsia.104,113,114 It is now widely hypothesized 
that placental synthesis of ROS followed by free radical-associated endothelial dysfunction 
may provide the link between reduced placental perfusion and the systemic maternal disease 
in preeclampsia.115
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Angiogenic factors 
Factors related to angiogenesis, the process of new blood vessel development from existing 
endothelium, have in the recent years been given much attention in preeclampsia research. 
Angiogenesis is essential for normal placental development, and is promoted by angiogenic 
factors released in placenta. Two extensively studied angiogenic factors, vascular endothelial 
growth factor (VEGF) and placental growth factor (PIGF), are suggested to be crucial for 
normal trophoblast proliferation and implantation116 and therefore normal pregnancy.117,118
VEGF has been proposed to be an useful marker of early vascular damage since it is secreted 
in response to tissue hypoxia and endothelial cell damage.119 Therefore changes in circulating 
levels of these angiogenic factors may be promising markers in the prediction of early-onset 
preeclampsia.120 Both placental levels of VEGF mRNA and maternal serum levels of PIGF 
have been shown to be much lower in preeclamptic women compared to normal pregnant 
women.121 However, many of the recent studies have concentrated on factors which 
antagonize VEGF and PIGF to assess their role in the development of preeclampsia. Two key 
anti-angiogenic factors, also produced by the placenta, are soluble fms-like tyrosine kinase 
(sFlt-1) and soluble endoglin (sEng). Both these factors have been implicated in the 
pathogenesis of preeclampsia whereby they have been shown to be over abundant in 
preeclamptic women compared to non-preeclamptic women.116,122-129 However, this is not 
always the case, some preeclamptic women have sFlt-1 within the normal range.72
1.5.2 The immune maladaption view 
The cornerstone of the immune system is the recognition of "self" versus "non-self", 
implicating that donor organ transplants expressing human leukocyte antigens (HLAs) 
different from the recipient’s will be rejected. However, in a normal pregnancy the fetal 
allograft presenting paternal antigens considered “non-self” by the maternal host is accepted. 
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An uteroplacental immune privilege is developed as a consequence of cooperative interactions 
between the fetus and the mother (reviewed in 130). The tissues located at the immune 
privileged maternal-fetal interface (placenta, decidua) are protected against cytotoxic T 
lymphocyte (CTL)-mediated destruction by not expressing the polymorphic classic class-I 
HLA molecules, apart from HLA-C.131,132 Instead the invading fetal trophoblasts express the 
non-classical molecules HLA-G,133 -E and -F,134 thus excluding them from being destroyed 
by the natural killer (NK) cells which are programmed to recognize HLA-null cells. Other 
factors expressed by trophoblasts, such as death-inducing members of the TNF superfamily 
ligands (e.g. FasL and TNF- Į) also confer to immune privilege.135-140
In a preeclamptic pregnancy however, the maternal  “acceptance” of the fetus allograft is 
perturbed in a manner akin to the immunological dynamics as seen in organ graft rejection.141
The maternal-fetal immune maladaption has been suggested resulting from a disturbed 
interaction between the maternal NK cells and invading fetal trophoblasts, which are 
suggested to contribute to the depth of trophoblast cell invasion during 
implantation/placentation.142 The depth of trophoblast cell invasion is pertinent to successful 
pregnancies whereby inadequate, shallow trophoblast cell invasion is a precursor to 
insufficient decidual spiral artery remodeling.
The placenta is a source of many immunomodulatory hormones and cytokines, and several of 
these factors are suggested to be released at the maternal-fetal interface or into the maternal 
circulation contributing to the regulation of the local and systemic immune changes required 
for a successful pregnancy.143,144 Preeclampsia has been shown to be associated with aberrant 
placental production of immunomodulatory factors.145,146 An abnormal activation of the 
maternal immune system has been reported in preeclampsia (reviewed in 147,148), with an 
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impaired activation of immune cells like Th1/Th2 and NK cells.149,150 This fits with the 
general assumption that the heterogeneous maternal symptoms of preeclampsia may all be 
ascribed to a generalized endothelial dysfunction,88 which contributes to an exaggeration of 
the systemic inflammation that occurs in normal pregnancy.75
Inflammatory mediators 
In general, cytokines which are central players of the inflammatory response are secreted by 
both the immune system and adipocytes.151,152 The enhanced inflammatory state observed in 
preeclampsia is associated with maternal leukocyte activation, increased cytokine release and 
interaction between leukocytes and endothelial cells.153 The circulating levels of TNF-Į and 
interleukin-6 (IL-6), that are elevated in normal pregnant women compared to non-pregnant 
controls, are further raised in preeclamptic women.154-158 Increased serum or plasma levels of 
other pro-inflammatory cytokines and of their modulators, such as IL-2, IL-8, IL-12, IL-15 
and IL-18. The IL-1 receptor antagonist (IL-1Ra), soluble IL-4 receptor and soluble TNF 
receptor have also been observed.155,159-164 Cytokine imbalance and elevated expression of the 
pro-inflammatory molecules TNF-Į, IL-1 and IFN-Ȗ are also evident in preeclamptic 
placentas,165-168 and it is undoubted that a placental contribution is likely to be significant. 
However, the cellular source of pro-inflammatory cytokines in preeclampsia has been difficult 
to identify. The main pro-inflammatory cytokines TNF-Į and IL-1 stimulate both structural 
and functional alterations in endothelial cells,169 and placental TNF-Į and IL-1 have been 
suggested to be potential mediators of maternal endothelial dysfunction in preeclampsia.  
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1.6 Genetics 
1.6.1 The DNA revolution 
The determination of the three-dimensional structure of DNA in 1953 by James Watson and 
Francis Crick170,171 revolutionized science and the made basis for new research. Knowing the 
DNA's structure immediately solved one of biology's greatest mysteries - how genetic 
instructions are passed on from one generation to the next. This finding opened the door to 
what has become one of the hottest areas of medical research – genetics. Human genetics 
describes the study of inheritance as it occurs in human beings, while medical genetics seeks 
to understand how genetic variation relates to human health and disease. Research on the 
causes and inheritance of genetic disorders can be considered within both human and medical 
genetics.
Although the structure of DNA showed how inheritance worked, it was still not known how 
DNA influenced the behavior of cells, which are the fundamental working units of every 
living system. All the instructions needed to direct their activities are contained within the 
DNA. The human genome project was started in 1990, and among the goals of this project 
was to identify all of the approximately 25,000 genes in the human DNA and to determine the 
sequence of the approximately 3 billion chemical base pairs that make up the human DNA 
sequence. Sequencing of the human genome172,173 was completed in 2003, and the technology 
and resources generated by this project are already having a major impact on research across 
the life sciences.  
The genome of any two unrelated individuals is close to identical (99.9%),174-177 but many 
genetic variations in the human genome have been observed. The two most important 
structural classes of sequence variation are microsatellites or short tandem repeat 
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polymorphisms (STRs) and single nucleotide polymorphisms (SNPs). Microsatellites are 
tandem repeats of a simple DNA sequence consisting of single repetitive nucleotide or di-, tri-
, tetra-, or pentanucleotide repeats. Microsatellites are highly variable and most people are 
heterozygous at any given locus, meaning that one can distinguish between the maternally and 
paternally inherited alleles. The alleles are differentiated by the number of repeats (e.g. 
(CAG)n indicates that the CAG 3-base sequence is repeated n times). Microsatellite sequences 
tend to appear in non-coding regions, while SNPs, representing variation at a single 
nucleotide position, are distributed throughout the genome in both coding and non-coding 
regions. SNPs are the most abundant form of genetic variation and at present there have been 
identified more than 14.5 million RefSNP in the human genome, approximately 6.5 million 
being validated.(www.ncbi.nlm.nih.gov/SNP/snp_summary.cgi) The genetic differences 
observed between humans are caused by genetic recombination and various mutational 
events. Two unrelated individuals are expected to differ at approximately 1 in 500-1,000 
nucleotides174-177 and these differences provide a wealth of information regarding the 
elements responsible for the phenotypic differences among them. Natural selection and a high 
degree of neutral mutations mainly due to genetic drift are causes for the genetic variation 
observed at a population level. A central goal of genetics is to pinpoint the DNA variants that 
contribute most significantly to population variation in various traits. Human genetic diversity 
appears to be limited not only at the level of individual polymorphisms, but also in the 
specific combinations of alleles (haplotypes) observed at closely linked sites.178-182 An 
important aspect of SNPs with regard to their use in whole-genome scans is that they can be 
inherited together in haplotype or linkage disequilibrium (LD) blocks.183,184 LD describes a 
situation in which some combinations of alleles or genetic markers occur on the same 
haplotype more or less frequently in a population than would be expected. Non-random 
associations between polymorphisms/alleles at two or more different loci are measured by the 
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degree of LD. Haplotype or LD blocks consist of SNPs in LD with each other where little 
historical recombination has occurred. Therefore, as genotypes of SNPs in the same block 
tend to be correlated, not all SNPs in a block need to be directly assayed. The International 
HapMap Project185 aimed to develop a haplotype map of the human genome thereby 
characterizing the structure of sequence variation throughout the genome of various 
populations and to make this information freely available in a public domain. This has 
provided a guide for selecting SNP markers for mapping genes underlying common, 
multifactorial disorders. Regions of LD were mapped out, leading to the opportunity of 
performing whole genome scans based on indirect association. The use of SNPs has 
revolutionized human genetics and a new paradigm has been introduced into genomic 
research with the HapMap, by making possible the cost-efficient assessment of much of the 
common genomic variation within an individual.186,187 In regions of high LD, i.e. strong 
association between SNPs, it is appropriate to genotype only a few, carefully chosen 
haplotype tagging SNPs (tag SNPs) since these will provide enough information to predict 
much of the information about the remainder of the common SNPs in that region. This 
together with development of appropriate genotyping methods and analysis has now made it 
possible to perform a genome-wide association study (GWAS) for up to 1 million SNPs at a 
time. 
Hardy-Weinberg equilibrium (HWE) is the fundamental starting point for all population-
based genetic investigations, whether the goal is detection or estimation of the effects of all 
the factors that disrupt HWE. HWE states that both allele and genotype frequencies in a 
population normally remain constant from generation to generation.188 The principle of HWE 
provides a baseline to determine whether or not gene frequencies have changed in a 
population and thus whether evolution has occurred. Deviations from HWE can be due to 
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non-random mating (inbreeding), population admixture or stratification, limited population 
size, mutations, random genetic drift and gene flow. Random genetic drift refers to evolution 
occurring through random changes in allele frequency over time, while gene flow refers to 
evolution that occurs because individuals move among populations. Sampling error including 
genotyping error can also lead to deviation from HWE, and researchers often test for HWE as 
a data quality check. However, deviation from HWE can also result from disease 
association.189 The possibility that a deviation from HWE is due to a deletion 
polymorphism190 or a segmental duplication191 that could be important in disease causation, 
should be considered before discarding loci. 
1.6.2 Study design 
The study design is crucial for the chances of a successful outcome in genetic studies. 
Attention should be paid to both ascertainment and experimental design, in order to maximize 
the power of a study. Knowledge about the phenotype of interest is also important. Cost has 
been and still is an important limiting aspect when planning a genetic study, especially 
association studies. The cost of a genetic study is largely determined by the number of 
individuals to be recruited, phenotyped, and genotyped, however the number of markers to be 
typed also plays a role. Thus an optimal strategy for balancing cost and power of the study 
should be determined. Until recently investigators were not able to perform GWA studies, due 
to the limited access to affordable genome-wide SNP typing technology. Although, 
genotyping technology has considerably improved and become cheaper, investigators are now 
faced with new challenges such as choosing platforms and products best suiting their 
research. In addition to overall cost, one must consider the coverage, efficiency, and 
redundancy of a platform. 
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Genome-wide linkage analysis 
A genome-wide scan (genetic linkage analysis) to map regions of the genome (loci) that 
contain genes that predispose to disease is generally the first step in unraveling genetic 
patterns and inheritance. Linkage extends over much longer regions of the genome than does 
LD, and linkage analysis often identifies broad genomic regions that might contain a disease 
gene or genes. Linkage describes the association of two or more loci on a chromosome with 
limited recombination between them. In other words, two genetic loci are linked if they are 
transmitted together from generation to generation more often than expected under 
independent inheritance (i.e. more than 50% of the time). The reason alleles at two linked loci 
tend to be co-inherited is that recombination is unlikely to occur between them in a given 
meiosis, because of their physical proximity. Families with increased occurrence of the 
disease of interest are very useful in linkage studies. Multiple-case families are most likely to 
carry a strong genetic predisposition. In addition, related individuals are very similar in their 
genetic material (DNA) making the search for regions containing disease genes easier to 
detect when comparing affected and healthy individuals.
By genotyping genetic markers (microsatellites or SNPs) at regularly spaced intervals across 
the genome and studying their segregation through families, it is possible to infer their 
position relative to each other on the genome. If a given marker tends to be passed down 
through a family in conjunction with a disease, this suggests that a gene with a functional 
effect, potentially due to causative genetic variant(s), is located in close proximity to that 
marker. However, this does not mean that the marker and the causative variant(s) are within 
the same gene but may lie within a particular genomic interval. Linkage analysis, particularly 
in studying complex diseases, can only identify large genetic regions. These linkage regions 
often contain hundreds of genes, many of which may seem like plausible biological 
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candidates. The identification of genomic regions linked to a particular disease posits the next 
challenge to prioritize positional candidate genes for further investigation. 
Genetic association analysis 
Genetic association studies aim to identify loci that contribute to disease susceptibility by 
comparing patterns of genetic variation between individuals with a disease (cases) and those 
without (controls).187 The principle aim of this approach is to detect association between 
genetic polymorphism(s) within gene(s) and a trait or disease of interest. There are two types 
of association studies: the candidate-gene approach (hypothesis driven) and the genome-wide 
approach (hypothesis generating). In this section, the candidate-gene association approach is 
in focus, whereas the genome-wide approach is described in chapter 6. In genetic association 
studies an a priori assessment of candidate genes relevant to the pathophysiology of the 
disease of interest are made, usually on the basis of biological hypotheses or the location of 
the candidate within a previously determined region of linkage. Association differs from 
linkage in that the same allele(s) is associated with the trait in a similar manner across the 
whole population, while linkage allows different alleles to be associated with the trait in 
different families.192 The fact that association operates only over short distances in the 
genome has for long guaranteed association studies an important place in fine mapping 
genetic loci initially detected by linkage. It is now widely accepted that genetic susceptibility 
to common complex disorders probably involves many genes, most of which have small 
effects. Association studies have greater power than linkage studies to detect small effects.192
In addition, a large number of SNPs throughout the genome has been identified and 
development of technology enables genotyping of numerous SNPs (1,000,000)
simultaneously. Another fact is that genotyping costs are continuously falling. Taken together, 
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this has led to an increasing importance of association studies in genetic epidemiology and 
biomedical research.  
There are two types of association analysis; 1) direct which is based on a functional genetic 
variant and 2) indirect which is based on a non-functional variant being in LD with a 
functional variant (Figure 2). In fact, the indirect association analysis (LD analysis) is a form 
of linkage analysis since it is hypothesized that affected individuals share their phenotype 
because they also share some disease-predisposing allele identical by descent from a common 
ancestor. LD analysis allows finer mapping than conventional linkage analysis. In situations 
where the locus variation itself has a direct effect on a trait variation, association studies are 
more powerful than linkage studies because the causal risk factor is measured.192 However, 
with modern exploratory strategies it is less likely that causal variants are measured directly, 
and more likely that neighboring polymorphisms in LD are found to be associated. In these 
situations the power to detect a trait locus is dependent on the strength of the LD and similar 
to the recombination fraction in linkage analysis.193
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In association studies the standard study design is to collect a number of unrelated affected 
(case) and unaffected (control) individuals from a homogeneous population. Then the 
genotypes of a marker locus or loci are tested to evaluate their frequencies between the case 
and control groups. An alternative design is to collect triads, consisting of two parents and 
one offspring. Depending on the trait/disease of interest either one of the parents or the 
offspring may be affected, or one may compare case triads to control triads. Association 
studies can also be carried out in multiple families, however family-based studies suffer from 
several disadvantages such as potential ascertainment bias toward early age of onset if living 
parents are required, difficulty of recruiting related individuals, and they require different 
analytical methods that account for the expected correlation in genotypes between related 
individuals.194
Finally, to evaluate whether candidate genes showing a nominal association with a disease 
exhibit a general role in the development of disease, the same, associated, variant needs to be 
tested in several independent populations, so-called replication studies. 
1.6.3 The role of genetics in preeclampsia 
Studying the familial aspects of preeclampsia led to the discovery of preeclampsia as a 
disease exhibiting heritable characteristics, which means it has a genetic basis. Adams et al. 
observed a strong familial tendency to preeclampsia and hypertension in pregnancy, finding 
that 49% of the sisters of preeclamptic women had themselves experienced these 
conditions.195 Several studies have since then confirmed these findings and observed an 
increased frequency of preeclampsia among mothers, daughters, sisters, and granddaughters 
of women who had this syndrome.195-202 In addition to the maternal genetic factors, fetal 
genetic factors also appear to contribute to preeclampsia susceptibility, via paternal 
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transmission.70,203 In a retrospective Norwegian study of births (data from the MBRN) it was 
shown that males born from a preeclamptic pregnancy presents a moderate risk (1.5-fold) to 
father a preeclamptic pregnancy.70 Genetic factors are suggested to be responsible for more 
than 50% of the liability to preeclampsia196,204,205 but the exact pattern of inheritance is still 
unknown.
Efforts to elucidate genetic susceptibility for preeclampsia has uncovered evidence for 
maternal susceptibility loci and locus heterogeneity amongst Icelandic,206 Australian/New 
Zealand (Aust/NZ),204,207-209 Dutch210,211 and Finnish212 family cohorts (Table 2).  
Table 2: Genome-wide linkage studies in preeclampsia families. 
Country Chromosome with 
significant linkage 
Chromosome with 
suggestive linkage 
Publication(s) 
Iceland 2p13 2q23 Arngrimsson et al. 1999206
Australia/
New Zealand 
2q22, 5q, 13q 4q34, 11q23 Moses et al. 2000,207 Johnson et al. 
2007,209 Harrison et al. 1997213
Netherlands  10q, 12q, 22q Lachmeijer et al. 2001211
Finland 2p25, 9p13 4q32 Laivouri et al. 2003212
The genome-wide scan in the Icelandic families revealed a maternal susceptibility locus for 
preeclampsia on chromosome 2p13.206 In the Aust/NZ family cohort linkage to chromosome 
2 was confirmed by identification of significant linkage on 2p12 and suggestive linkage on 
2q23.207 It was suggested that the Icelandic and Australian findings represented the same 
chromosomal region on 2p. But subsequent analyses of the Aust/NZ genome-wide linkage 
scan data set, applying a variance components-based procedure, resolved and strengthened the 
chromosome 2 linkage signal to 2q22.204 This analysis approach also identified two novel 
preeclampsia susceptibility quantitative trait loci (QTLs) on chromosomes 5q and 13q.209 A 
quantitative trait, also called continuous trait, varies over a continuous range of phenotypes 
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and stands in contrast to qualitative, or discontinuous, traits that are expressed in the form of 
distinct phenotypes chosen from a discrete set. The appearance of a quantitative trait usually 
signifies the involvement of multiple genetic loci, although this does not need to be the case. 
In particular, a single polymorphic locus with multiple, differentially expressed alleles can 
give rise to continuous variation within a natural population. Multifactorial traits outside of 
illness contribute to what we see as continuous characteristics such as blood pressure and 
height which can be measured by some quantitative means. These traits generally exhibit a 
normal continuous distribution. A genome-wide linkage scan of the Finnish families has also 
confirmed linkage on chromosome 2, however at a different locus, 2p25, than the Icelandic 
and Australian loci.212 In addition, significant linkage was identified on chromosome 9p13 in 
the Finnish families, which has been shown to be a candidate region to type 2 diabetes in 
Finnish and Chinese families.214,215 The genome-wide scan of Dutch affected sib-pair families 
did not confirm linkage on chromosome 2, but revealed two peaks with suggestive evidence 
for linkage on chromosome 10q and 22q.211
While the familial association of preeclampsia has been recognized for decades, identification 
of susceptibility genes for preeclampsia has proven to be more difficult. A reason for this is 
that the genetics of preeclampsia fits the disease characterization of complex human disorder 
with multiple genetic effects (e.g. more than one gene) with no clear pattern of genetic 
inheritance in combination with environmental factors (e.g. lifestyle). It has been said that the 
cause of “any” disease is immunological, vascular, metabolic, genetic or a consequence of 
trauma.216 In the etiology of preeclampsia all of these causes except for the last one have been 
considered central.217-220 However, there is a growing acceptance that related common 
diseases previously considered to be multi-factorial and primarily immunological, vascular or 
metabolic (e.g. multiple sclerosis, essential hypertension and type 2 diabetes, respectively), 
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are in fact genetic.221 In complex human disorders like preeclampsia the end phenotype is a 
result of multiple susceptibility loci each having a modest contribution and highly likely an 
interactive effect.222 Figure 3 (modified after 223) gives an overview of interactions between 
causal factors resulting in preeclampsia, and shows that all these factors could potentially be 
due to genetic predisposition. 
1.6.4 Preeclampsia candidate genes 
Studies of more than 50 candidate genes have been reported, but these have so far failed to 
identify universally accepted susceptibility genes (reviewed in 224,225). Approximately 70% of 
the published candidate gene studies in preeclampsia have focused on only eight genes.226 The 
majority of the candidate gene studies have also addressed the role of maternal genotype, 
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however one large multicenter study addressed the contribution of both maternal and fetal 
genes.227 Major risks associated with a number of SNPs in the candidate genes that have 
dominated the studies of the genetics of preeclampsia were excluded by this study.227
Unraveling the genetic contribution of preeclampsia still remains one of the most 
fundamentally important challenges in obstetric medicine.228,229
The candidate genes studied in preeclampsia can be subdivided into different groups 
according to their assumed role in the pathophysiology; genes encoding 1) proteins that are 
vasoactive and involved in vascular remodeling, 2) proteins involved in thrombophilia, 3) 
proteins involved in oxidative stress, lipid metabolism and endothelial injury, 4) 
immunoregulatory proteins, 5) proteins involved in placentation and 6) growth factors.224 In 
addition, there is a small number of promising positional candidate genes that has been 
studied. Positional candidate genes are genes residing within a chromosomal region 
previously shown to be in linkage with disease susceptibility. 
Vasoactive proteins and vascular remodeling  
Genes encoding components of the renin-angiotensin-aldosterone system (RAAS) seem to be 
plausible candidates for involvement in the etiology of preeclampsia, due to the central role of 
RAAS in BP regulation, vascular remodeling and body-fluid volume during pregnancy.66,230
Genetic polymorphisms in angiotensin converting-enzyme (ACE), angiotensinogen (AGT)
and angiotensin II type 1 and 2 receptors (AGTR1, AGTR2) have been studied extensively 
with inconsistent results (reviewed in 224). Dysfunction of another system, the VEGF system, 
has been associated with development of preeclampsia. The soluble form of the VEGF 
receptor, sFlt-1, acts as an antagonist for VEGF and PIGF129,231 and has been shown to be up-
regulated in preeclampsia.116,122-124,126,128,129 It has been proposed that sFlt-1 might trigger 
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endothelial dysfunction, and that this factor might link placental ischemia and the maternal 
disease since its production is induced by hypoxia. Dysfunction of the VEGF system has also 
been suggested to contribute to reduced invasion of trophoblasts.116,117,232,233 At the mRNA 
and protein level there is evidence of association between factors belonging to the VEGF 
system and preeclampsia,121 but no polymorphisms in these genes that could possibly be 
related to this effect have been identified so far. Other vasoactive proteins that have been 
suggested to be involved in development of preeclampsia are sEng, endothelin-1, estrogen 
receptors Į and E and endothelial nitric oxide synthase (eNOS). However, the number of 
studies that have investigated SNPs in the genes encoding vasoactive proteins is rather small 
and to date none of them have been identified as major determinants of preeclampsia risk. 
Thrombophilia
Association between inherited thrombophilia and severe preeclampsia has been reported.234
Due to the characteristic features of placental infarctions and villous thrombosis in 
preeclampsia, thrombophilic gene mutations have been suggested as predisposing factors. 
Functional mutations in the Factor V Leiden (FVL), prothombin and 
methylenetetrahydrofolate reductase (MTHFR) genes have been discovered.235 However, the 
studies of maternal genotypes of these genes published are controversial. Fetal trombophilic 
mutations have also been suggested to be associated with preeclampsia, but have not yet been 
detected with statistical significance.196,236-242
Oxidative stress, lipid metabolism and endothelial injury 
The evidence that placental oxidative stress play a central role in the pathogenesis of 
preeclampsia is increasing.243 Genes involved in generation of or protection against ROS 
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therefore seems like plausible candidates for preeclampsia. Only a few studies have addressed 
the possible relation between preeclampsia and oxidative stress genes, such as epoxide 
hydrolase,244-246 glutathione S-transferase,247-250 cytochrome P4501A1248,250 and superoxide 
dismutase (SOD)246. Only polymorphisms in the epoxide hydrolase and glutathione S-
transferase genes have shown an association with risk for preeclampsia susceptibility,244-
246,250, however, these results are conflicting.246,247
Abnormal lipid metabolism is associated with oxidative stress and an abnormal lipid profile, 
potentially contributing to endothelial dysfunction, has been shown in women with 
preeclampsia.251 Lipoprotein lipase and apolipoprotein E (ApoE) are two major regulators of 
lipid and lipoprotein metabolism, thus these genes have been proposed as possible candidates 
for preeclampsia.66,252 Studies of maternal alleles and polymorphisms in the lipoprotein lipase 
and ApoE genes have given inconsistent results regarding their association with 
preeclampsia.252-260 A recent study proposes that the fetal genotype in the lipoprotein lipase 
and ApoE genes is important to the metabolism of maternal lipoproteins,261 suggesting that 
future investigations should focus on both maternal and fetal genotype. 
Immunoregulators
Genes encoding the various aspects of the immune system may be good candidates for 
involvement in preeclampsia development, due to the central role the maternal-fetal immune 
maladaption has been ascribed in the pathogenesis (reviewed in 66,220). Several HLA 
molecules (HLA-DR, -A, -B, -DQ, -G, -C) have been suggested as candidate genes for 
preeclampsia, but the data remain inconclusive (reviewed in 262). Maternal-fetal allele sharing 
is proposed to be a focus in future studies of HLA molecules. Another immunoregulatory 
protein suggested to play a role in the development of preeclampsia is TNF-Į. TNF-Į is 
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suggested to be important in early pregnancy by promoting growth, differentiation and normal 
placentation.158,263,264 Elevated levels of TNF-Į and TNF receptors in plasma and amniotic 
fluid of preeclamtic women157,158 may contribute to vasoconstriction and platelet aggregation 
via increasing levels of thromboxane.263,265 In addition TNF-Į is involved in generation of 
ROS and may influence the susceptibility of oxidant-mediated injury in the endothelium.265
Several studies have investigated TNF-Į promoter polymorphisms, with some reports 
showing association with preeclampsia265-268 or eclampsia269 with as many other studies 
finding no association227,263,268,270-273. Genes encoding interleukins have also been suggested 
as candidate genes for preeclampsia. Polymorphisms in the genes encoding IL-1E and IL-1Ra 
have been shown to alter protein expression,274,275 but there seems to be a lack of association 
with preeclampsia in the few studies performed.267,274,276,277 Gene expression (mRNA) of the 
anti-inflammatory cytokine IL-10 have been shown to be reduced in preeclamptic 
placentas,267,278 and some studies have identified association between variants in this gene and 
preeclampsia risk.270,279,280 However, similar to many of the other candidate genes described 
the results for the IL-10 polymorphisms remain controversial.267,273,279,280
Placentation 
Genes involved in placentation have been suggested to be good candidate genes for 
predisposing to preeclampsia due to their obvious connection to placental function (reviewed 
in 229). Based on studies in mice, the best candidates for preeclampsia development seem to be 
genes that are involved in differentiation and maintenance of trophoblast cells.66,281,282
However, the role of these genes in preeclampsia remains to be investigated. Transcriptional 
profiling in placentas from preeclamptic women has also identified genes likely to be 
involved in placentation as relevant genes in the pathogenesis of preeclampsia. Among these 
are trophoblast-invasion associated genes, such as matrix metalloproteinases (MMPs)283 and 
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apoptosis related genes, such as cyclin and p53,284. Also leptin, shown to have a stimulatory 
effect on trophoblast invasion in vitro,285,286 and the potential leptin receptor siglec-6 has been 
proposed to affect trophoblast invasion.287 Increased circulating levels of leptin have been 
reported to be associated with preeclampsia in several studies,8,288-295 and a leptin gene 
polymorphism has been linked to preeclampsia susceptibility.296 Interestingly, singlec-6 is 
restricted to B lymphocytes and human placenta, in other species placental cells lack singlec-6 
expression.297 Since preeclampsia is thought to be a disease unique to humans this is 
extremely intriguing. The present data on placentation genes is scarce, but current findings 
suggest that research in this area deserves attention and should encourage intense 
investigation.
Growth factors 
Insulin-like growth factors (IGFs) are involved in regulation of fetal and placental growth 
throughout gestation,298 and IGF-II may be important for both trophoblast and decidual 
function.299 In normal pregnancies, maternal serum levels of IGF-I increase from 
midgestation.300 However, an increase in serum concentration of IGF-I from first to second 
trimester has been shown to be associated with an increased risk of developing preterm 
preeclampsia.301 Insulin-like growth factor binding protein-1 (IGFBP-1) is thought to inhibit 
local IGF activity and to reduce trophoblast invasion early in pregnancy.302,303 In a recent 
study, low levels of IGFBP-1 in first and second trimester were shown to be associated with 
an increased risk of term preeclampsia.301 A congenital disorder involving fetal and postnatal 
overgrowth, Beckwith-Wiedemann syndrome, has been associated with both IGF-II over 
expression and severe early-onset preeclampsia. This suggests a possible link between genetic 
variations in IGF-II and development of preeclampsia by restricting intrauterine fetal 
growth.66,304,305 Genotyping of a ApaI restriction-fragment-length polymorphism in IGF-II
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showed no association with preeclampsia.304 Contribution of an intronic SNP in the IGF-I
gene has recently been suggested, although the result was not statistically significant after 
adjustment for multiple hypothesis testing.273
Positional candidate genes
A gene coding for a transcription factor that is expressed in EVTs, storkhead box 1 (STOX1), 
was identified as a promising positional candidate gene for preeclampsia.306 This gene is 
located within a region on chromosome 10q that showed suggestive linkage to preeclampsia 
in Dutch families,210 and is known to be expressed in the placenta during invasion of the 
uterus in early pregnancy. It was concluded that STOX1 is a maternal effect gene due to the 
observation that women with preeclampsia inherited a version of the gene with reduced 
function from their mothers. Over the past decade genomic imprinting has been strongly 
suggested to play a role in the preeclampsia pathogenesis, due to its role in placental and 
embryonic/fetal development.307,308 Due to mutation or loss of a single active copy with an 
unusual mode of inheritance imprinted genes may influence trophoblast growth or fetal 
development that causes disease. Subsequent studies have not been able confirm an 
association of STOX1 with preeclampsia.309,310 Also our genotyping results in the HUNT 
preeclampsia case-control cohort contradict an association between STOX1 and preeclampsia 
(Fenstad et al., in preparation).
Activin receptor type II A (ACVR2A) is another gene that has been proposed as a positional 
candidate gene for preeclampsia.204 This gene resides within chromosome 2q22 which has 
been shown to be in significant linkage with preeclampsia in Aust/NZ families. Moreover, a 
gene expression study in decidual tissue showed ACVR2A to be more than 10-fold down-
regulated in preeclamptic compared to normotensive women.204 ACVR2A is a receptor for 
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activin A which appears to have a fundamental function during implantation and 
decidualization,311,312 and modulates placental production of hormones313 and secretion of 
uterotonin314. In preeclamptic women elevated serum levels of activin A have been 
detected.315-320 Altered expression of ACVR2A, possibly due to polymorphisms in this gene, 
and its effect on activin A function may influence the central pathophysiologic features of 
preeclampsia by impairment of trophoblast invasion and remodeling of spiral arteries.204
Results from genotyping five ACVR2A SNPs in Aust/NZ families showed preliminary 
evidence of association with preeclampsia for three of them.204
In addition positional candidate genes encoding the endoplasmic reticulum aminopeptidase 
enzymes (ERAP1 and ERAP2) and a placental peptide hormone corticotrophin-releasing 
hormone-binding protein (CRHBP) on the Australian 5q QTL and genes encoding type IV 
collagens, alpha-1 (COL4A1) and alpha-2 (COL4A2) on the Australian 13q QTL have been 
suggested as plausible candidates.209 These genes are all positional candidate genes with 
major “hit-scores” obtained from a computer program used to objectively prioritize genes 
under defined QTLs. All these genes are expressed in the placenta, and thus, are potentially 
involved in preeclampsia development. 
The current status of candidate gene studies in preeclampsia  
Very few of the candidate genes studied to date are located within chromosomal regions 
shown to be in significant linkage with preeclampsia. The majority of the candidate genes 
have rather been selected based on biological hypotheses and their role in biological pathways 
relevant to the pathology of preeclampsia. Most of these genes have shown inconsistent 
association with preeclampsia. To date, the current literature suggests two promising 
positional candidate genes, STOX1 and ACVR2A, have been reported after follow-up studies 
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on linkage detected on chromosome 10q210,306 and 2q204,321,322, respectively. In conclusion, 
data remain inconclusive for the large panel of candidate genes for preeclampsia tested so far. 
However, genome-wide linkage analysis and subsequent analysis using novel approaches 
such as objective prioritization of positional candidate genes, have generated encouraging 
results.
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2 AIMS OF THE STUDY  
The aim of this dissertation was to identify genes contributing to increased maternal risk of 
developing preeclampsia, particularly focusing on: 
I. Positional candidate genes
a) within the Australian 2q QTL 
b) within the Australian 5q QTL 
c) within the Australian 13q QTL 
II. Candidate genes involved in inflammation and oxidative stress 
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3 MATERIALS AND METHODS 
3.1 The HUNT population 
The second Health Study of Nord-Trøndelag (HUNT2), a multipurpose health survey 
focusing on the total population in the rural county of Nord-Trøndelag, Norway, took place 
during 1995-1997. Nord-Trøndelag County is located in the middle of Norway (Figure 4), and 
is a representative of Norwegian geography, economics, industry, age distribution, morbidity 
and mortality.323 The population in Nord-Trøndelag is ethnically homogenous with less than 
3% non-Caucasians, making it suitable for epidemiological genetic studies.323,324 All county 
citizens aged 20 years or older (n=92,566) were invited and 71.2% participated (n§65,900).
The invitation comprised a health questionnaire, a clinical examination and blood tests 
(including peripheral leukocyte sampling).323
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3.2 Identification and classification of preeclamptic cases and controls 
In order to identify women who had been pregnant and if they had a normal or preeclamptic 
pregnancy in the HUNT population we had to use the Medical Birth Registry of Norway 
(MBRN). Since 1967 all deliveries in Norway after 16 weeks of gestation, more than 1.8 
million births, have been recorded in the MBRN.325 The registration is based on standardized 
forms completed by midwives and doctors at the delivery ward within one week (9 days) after 
delivery. All diagnoses recorded before discharge from the hospital are included in the 
registry. In the MBRN preeclampsia is usually recorded as a specified diagnosis. The medical 
birth registration form may also hold information about specific symptoms of preeclampsia, 
such as hypertension, proteinuria, or edema during pregnancy. From 1967 to December 1998 
women registered with ICD-8 codes. MBRN made extensions of the ICD-8 codes326 and these 
diagnosis codes or combinations of them defined preeclampsia in the present work (Table 3).  
Table 3. Preeclampsia ICD-8 codes and definition of preeclampsia in the present work. 
International ICD-8 codes 637.0 Preeclampsia  
637.1 Eclampsia  
637.9 Toxemia, unspecified 
MBRN ICD-8 codes 637.0 Hypertension developed during pregnancy 
637.2 Hypertension and edema 
637.3 Proteinuria without previous kidney disease 
637.4 Hypertension and proteinuria 
637.5 Hypertension, proteinuria and edema 
637.6 Threatening eclampsia 
637.9 Toxemia, intoxication, preeclampsia ina 
MBRN ICD-8 codes  and combinations 
of these defining preeclampsia in the 
work presented in this thesis 
637.0 + 637.3 
637.2 + 637.3 
637.4 
637.5 
637.6 
637.9 
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After the 1st of December 1998 the MBRN changed their routines and the registrations were 
thereafter based on ICD-10 codes. These are: O13 Hypertension during pregnancy without 
considerable proteinuria, O14.0 Moderate preeclampsia, O14.1 Severe preeclampsia and 
O14.9 Unspecified preeclampsia. After 1998 subgrouping of preeclampsia cases was 
performed using the ICD-10 codes, with information about clinical manifestations (severe, 
moderate) and time of onset (before or after 34 weeks of gestation). 
In Norway, every individual has a unique 11-digit personal identification number given at 
birth. This allows cross linkage of individuals between health registries and other databases. 
In the work presented in this thesis, women with preeclamptic (cases) and non-preeclamptic 
singleton pregnancies (controls) in the HUNT population were identified by staff at MBRN 
by linking the HUNT database to the database at the MBRN. The data was subsequently made 
anonymous and linked to the biological samples by staff at HUNT biobank. Women 
registered with multiple pregnancies (twins, triplets etc.) were excluded since this is known to 
be a risk factor for preeclampsia. The HUNT database included 1,179 women registered with 
preeclampsia (cases), and 2,358 women with a history of non-preeclamptic singleton 
pregnancies (controls) were selected. The controls were selected as the two non-preeclamptic 
women subsequent to a women registered with preeclampsia in the linked data file. Blood 
samples were available from 1,139 cases and 2,269 controls at the HUNT biobank.
3.3 Candidate gene prioritization and selection of SNPs 
We used the GeneSniffer (www.genesniffer.org) computer program to interrogate the LOD 
drop (99% confidence) intervals at the Australian 2q, 5q and 13q preeclampsia QTLs to 
prioritize positional candidate genes in silico. GeneSniffer is a tool that automates 
bioinformatics database mining from National Center for Biotechnology Information’s 
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(NCBI’s) Entrez Gene, Online Mendelian Inheritance in Man (OMIM) and PubMed databases 
to objectively identify plausible positional candidate genes residing under defined QTLs. 
Interrogation of these databases is performed using a set of key words specific for the disease 
of interest as input. The input key words are assigned a weighting score of 10, 5 or 1 (10 
being the highest) based on their relevance and significance to the studied disease. The 
keywords assigned a score of 10 were pre-eclampsia, preeclampsia, eclampsia, pregnancy-
induced hypertension, pregnancy induced hypertension, pregnancy hypertension, gestational 
hypertension, PIH, toxaemic pregnancy and decidua. The keywords assigned a score of 5 
were toxaemia, pregnancy, placenta, spiral artery, glomerular endotheliosis, implantation, 
trophoblasts, cytotrophoblasts, proteinuria and placental bed. The keywords that assigned a 
score of 1 were uterus, uterine, amnion, chorion, NK cell, hypertension, gestation, gestational, 
oedema, edema, maternal, endothelial, endothelium, haemostasis, coagulation, coagulopathy, 
thrombophelia, ischemia, hypoxia and allograft. Identification of homologues of each gene, 
under the linkage peak, was performed by BLAST and scored for content of their Entrez 
Gene, OMIM and PubMed entries. Each score was weighted in accordance with the degree of 
homology. For each gene a cumulative “hit-score” was calculated and shown as an output. 
The output was provided in an HTML format documenting all genes under an observed QTL 
region with the source of database hits and links to external databases for additional 
information. GeneSniffer can also incorporate observed logarithm of the odds ratio (LOD) 
score function within a QTL region to use the localization data as an additional weighting 
function in which genes are considered more relevant the closer they are to the observed QTL 
peak.
We used this data along with knowledge on current and emerging concepts of the 
pathophysiology of preeclampsia327 to select genes for further analysis. For the prioritized 
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genes we selected validated SNPs from NCBI’s SNP database (Homo sapiens dbSNP build 
125) for further genetic analyses. In selecting these SNPs our initial focus was on likely 
functional variants (coding sequence SNPs) and those in known gene regulatory regions 
(proximal promoter, 5 prime (5’) untranslated region (UTR) and 3 prime (3’) UTR). In order 
to sufficiently cover known SNP variation within some of the genes we also selected 
validated intronic SNPs. 
3.4 Genotyping
Genotyping refers to the process of determining the genetic make-up of an individual at a 
specific locus. The use of SNPs has revolutionized human genetics, and several platforms 
have been designed for the analysis of SNP genotypes, including gel and capillary 
(fluorescent) based electrophoresis, fluorescent read-out, oligonucleotide (bead-based) 
microarrays and mass spectrometry. Single SNP genotyping assays have the longest history, 
but the need for genotyping technologies in which one can study several SNPs more 
effectively has evolved as a result of The Human Genome project and the International 
HapMap project. Several high-throughput genotyping approaches, with a variety of platforms 
and chemistries, are now available so that researchers can study from several up to 1 million 
SNPs simultaneously. Three different assays for three different genotyping technologies were 
used to genotype samples in the Norwegian case/control cohort presented in this thesis; the 
Applied Biosystems’ TaqMan (paper III) and SNPlex assay (papers I, II, IV, V) and 
Sequenom’s iPLEX Gold assay (paper IV). An additional genotyping technology, Illumina’s 
GoldenGate assay, was used for genotyping samples from the Aust/NZ family cohort for data 
presented in papers IV and V.
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3.4.1 TaqMan assay 
The TaqMan assay is a single tube and single SNP real-time PCR based genotyping assay 
which exploits the 5’ to 3’ exonuclease activity of Taq DNA polymerase. The reaction utilizes 
two PCR primers and two allele specific oligonucleotide probes, each labeled with a different 
fluorophore (FAM and VIC) at the 5’ end and a non-fluorescent quencher (NFQ) at the 3’ 
end. During the PCR a perfectly matching probe which hybridizes to its target allele will be 
displaced and cleaved by the exonuclease activity of the Taq polymerase, resulting in the 
release of the fluorophore away from the NFO. A mismatched probe will not hybridize to its 
target and remain intact, free floating in solution with its specific fluorophore and NFQ. At 
the end point of the PCR fluorescent emission of one dye over the other indicates a 
homozygous sample, whereas fluorescent emission of both dyes indicates a heterozygous 
sample. An intact, non-hybridized probe emits no fluorescent signal when excited due to the 
NFQ via Förster resonance energy transfer (FRET). An overview of the TaqMan technology 
is showed in Figure 5328. In the work presented, the TaqMan assay was used to genotype a 
known functional SNP within a potential candidate gene, catechol-O-methyltransferase 
(COMT), for preeclampsia (paper III).
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3.4.2 SNPlex assay 
The SNPlex™ Genotyping System is a migration specific assay designed to discriminate 
alleles by the application of three SNP specific ligation probes. Two of the probes are allele 
specific oligos (ASOs) that are designed to discriminate the two alleles at each SNP locus and 
the third probe is a locus specific oligo (LSO) that is common to both SNP alleles. All three 
probes house an universal PCR priming site whilst the ASOs are designed with unique 
ZipCode identifiers that are used to hybridize to complementary ZipChute probes. The 
ZipChute probes are designed with mobility modifiers that provide unique migration patterns 
for each specific SNP within the ASO/LSO probe pool. The SNPlex system allowed 
multiplexing of up to 48 SNPs in one SNP pool (panel), at the time the work presented in this 
thesis was performed, meaning that one could examine up to 48 SNPs simultaneously for 
each individual DNA sample. Fluorescent intensity signals for each individual sample are 
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interpreted and subsequently calculated into three genotype clusters using Applied 
Biosystems’GeneMapper® Software (version 4.0). An overview of the SNPlex technology is 
shown in Figure 6328. The SNPlex assay was used to genotype SNPs within positional 
candidate genes within the chromosome 2q, 5q and 13q preeclampsia QTLs (papers II, IV and 
V), and also a known functional SNP within a potential preeclampsia candidate gene involved 
in inflammatory response, Selenoprotein S (SEPS1) (paper I). 
3.4.3 iPLEX Gold assay 
The iPLEX Gold assay on the Sequenom MassARRAY® Platform combines the benefits of 
robust single-base primer extension biochemistry with the sensitivity, speed and accuracy of 
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Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight mass spectrometry (MALDI-
TOF MS). Sequenom SNP genotyping uses a bead-less and label-free primer-extension 
chemistry to generate allele-specific products which are separated by their distinct mass.329
Differences in mass are automatically translated by the MassARRAY Typer software into 
specific genotype calls. The iPLEX Gold genotyping assay allows multiplexing of up to 40 
SNPs simultaneously, where differentiation of genotypes for each of the SNPs in one assay is 
a result of unique mass ranges for the extension primers. This assay is widely used for fine 
mapping and validation studies and for routine applications that employ fixed SNP panels. An 
overview of the iPLEX Gold assay technology is shown in Figure 7328. The iPLEX Gold 
assay was used to perform replication genotyping of SNPs within positional candidate genes 
within the chromosome 5q preeclampsia QTL (paper IV) showing nominal association with 
the SNPlex genotyping. 
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3.4.4 GoldenGate assay 
The GoldenGate assay is based on a combination of oligo ligation assay (OLA), allele-
specific extension reactions and universal PCR. Three oligonucleotides, two ASOs and the 
third is a LSO, are designed for each SNP. All oligos contain universal PCR primer sites and 
the LSO also contains a sequence complementary to tags present in a particular bead type.330
These three oligonucleotides hybridize to the DNA once it binds to the paramagnetic 
particles, successfully extended and ligated products are amplified by PCR with fluorescently 
labeled universal primers. Following PCR and some downstream processing, single-stranded, 
dye-labeled DNAs are then hybridized to their complement bead type on an array of beads 
carrying the sequences complementary to the locus specific tags. This hybridization step 
allows for the assay products to be separated for individual SNP readout. A high-resolution 
scanner detects the fluorescent beads and decodes the information used to generate the 
genotype calls. The GoldenGate assay is capable of multiplexing up to 1,536 (96-1,536) SNPs 
in a single tube with very high pass rates and accuracy.331 An overview of the GoldenGate 
assay technology is shown in Figure 8328. The GoldenGate assay was used to genotype SNPs 
within positional candidate genes within the chromosome 2q, 5q and 13q preeclampsia QTLs 
in the Aust/NZ family cohort (papers IV and V). 
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3.5 Statistical analysis 
The statistical analysis of genetic association data depends crucially on the study design. 
When deciding what type of data to collect, e.g. family or population, one to some extent 
predetermine what kind of statistical analysis will be most appropriate. This means that also 
statistical geneticists should also focus on study design and ascertainment, in order to improve 
power of studies so that the genetic basis of complex phenotypes can be better understood. 
Prior to our genotyping experiments power calculations were performed. Typing 144 SNPs in 
1,086 preeclamptic and the same number of control samples gave us 80% power to detect a 
marker that accounts for 2% of the variation.  
The increased focus on SNP genotyping has made it clear that new statistical methods are 
needed for LD mapping of complex trait genes,332-335 and has led to re-examination of 
mapping methodologies and study designs.332,336-339 Developments in biostatistics have been 
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lagging behind the capacity to generate SNP genotypes,340,341 and what the best way to apply 
SNPs and LD mapping data to the genetic epidemiology of common diseases has been 
unclear. However, in the recent years quite a few GWAS have mapped and replicated 
candidate SNPs by LD mapping, and this approach seems very promising.  
3.5.1 Association analysis 
Methods such as logistic regression, chi-squared (F2) tests of association, and odds ratios may 
be suitable in simple cases, e.g. when studying a single marker and are available from 
standard statistical packages.192 Logistic regression model log odds of disease as a linear 
function of underlying genotype variables, while a F2 test of association tests for 
independence of disease status and a genetic risk factor. Pearson’s F2 test was used in papers I
and III presented in this thesis. Tests of dichotomous traits in unrelated individuals involve 
testing for different allele or genotype frequencies among affected versus unaffected 
individuals. To test for association with quantitative traits in unrelated individuals linear 
regression methods are commonly used.194
A measured genotype test, which directly tests the effect of measured genotype on the 
phenotypic outcome,342 has been used in papers II, IV and V included in this thesis. In 
principle, the effect of measured genotypes can be assessed for any given phenotypic 
outcome, either qualitative (e.g. disease presence or absence) or quantitative. The measured 
genotype test used in paper II, IV and V uses a standard threshold model assuming an 
underlying normal distribution of liability. This threshold model and its assumptions are near 
identical to those used in standard logistic regression but benefits from the ease of 
interpretation with regard to genetic effects. The measured genotype test of association can 
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assess the extent of genotypic mean differences (or the liability or risk scale) between case 
and control singletons assuming a model of additive gene action.342
In studies in which LD between typed markers and causal locus is exploited it is preferable to 
use multilocus, also called multivariant, approaches to analysis instead of analysis of marker 
loci one at a time. Combining genetic information from multiple markers simultaneously 
provides greater power to detect QTLs than do tests of individual markers, unless there is 
large degrees of freedom. Multivariant approaches generally involve consideration of 
haplotypes which are promising in the study of the genetic basis of complex traits. But since 
the field of haplotype analysis is relatively new and continuously evolving the development of 
multilocus approaches has been challenging. However, in the recent years novel multilocus 
approaches combating the problem with large degrees of freedom have been developed. 
Transmission disequilibrium test (TDT) is one of the best known family-based association 
tests, and was first developed to test for linkage between alleles and phenotypes that is either 
causal or due to LD in qualitative (dichotomous) traits.343 The underlying presumption of the 
TDT is to assess the transmission of alleles from two heterozygous, unaffected parents to an 
affected offspring. In a basic triad pedigree-structure the transmission of one parental and one 
maternal allele is measured against the non-transmitted parental and maternal alleles, 
respectively. Transmitted alleles favoring affected offspring greater than 50% therefore 
indicate evidence of association with the studied phenotype or trait. The TDT alleviates 
potential population stratification problems that may arise in case/control studies and has been 
extended for use in studies of qualitative traits with various family designs, such as sib-ships 
with no parental genotypes and families with one available parent. It has also been extended 
for use in studies of quantitative traits, named quantitative transmission disequilibrium test
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(QTDT).344,345 Both the TDT and QTDT can be used in studies of genetic markers with 
multiple alleles.345,346 QTDT is LD analysis of quantitative and qualitative traits based on 
variance components. In paper IV and V presented in this thesis a QTDT347 for SNP 
association in the Aust/NZ familial cohort was conducted in SOLAR348. The QTDT 
procedure scores allele transmissions throughout the entire pedigree structure for quantitative 
or qualitative traits347 and it has been modified in SOLAR to work with discrete traits using a 
threshold model.349
3.5.2 Multiple testing 
Testing large numbers of markers (many different loci) for association with a particular 
disease or trait gives rise to the multiple testing problem, i.e. it is likely that some associations 
are found by chance and one obtains false positive results (type I error). The traditional 
solution is to use a Bonferroni correction, where the basic premise is to ensure that the 
overall probability of declaring any significant differences between all possible pairs of 
groups is maintained at some fixed significance level (Į). The Bonferroni method relies on the 
assumption that all tests are independent, however this is not likely to be true in genetic 
mapping studies due to LD and correlations among subsets of SNPs. In addition, the 
Bonferroni correction fails to consider the correlation among related phenotypes. Bonferroni 
correction works well with small numbers of tests. However, association studies have 
exploded, with hundreds of thousands of tests as in GWAS with 500,000 to 1 million SNPs, 
and at such a large scale, a Bonferroni type correction is not an attractive solution because of 
LD between SNPs close to each other. In fact Bonferroni correction will likely result in a 
large false negative rate (type II error). The Bonferroni method is considered excessively 
stringent. Due to this, various, less conservative methods have been devised in order to 
control for multiple testing issues and attempt to balance between the type I and type II errors.  
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To accommodate for multiple hypothesis testing in papers II, IV and V, the approach of Li 
and Ji350 was used to determine the effective number of independent SNPs (and tests) in 
combination with applying a false discovery rate (FDR) or permutation analysis. The 
algorithmic approach of Li and Ji evaluates the strength of correlation amongst the observed 
genotypes at each SNP locus within a gene and has been implemented into SOLAR. 
Permutation testing is a simulation-based re-sampling technique that compares observed p-
values with p-values calculated from simple repeated perturbations of the data. In this 
approach, two files are created, one with all of the genotypes for each individual, and one 
with all of the phenotypic data. By randomly permuting just the individual identifiers for one 
of the two files, the correlation among genotypes is preserved, as is the correlation among 
phenotypes, but any association between genotype and phenotype is broken. The complete set 
of association tests is then performed on the permuted data, and the permutation process is 
repeated thousands of times. This process generates a distribution of the best p-value expected 
in the entire experiment under the null model of no association between genotype and 
phenotype, allowing estimation of “experiment-wide significance.” If an association has a 
nominal p-value of 0.001, and a p-value of 0.001 or lower is observed 60 times in 1000 
permutations, then the corrected, empirical experiment-wide p-value is 0.06. The advantages 
of permutation testing are that these methods are robust and useful in achieving good type I 
rates and power, and appropriate for any test statistic regardless of whether the underlying 
distribution is known. A major disadvantage of these methods is that they can be 
computationally intensive and may require complex programming skills and statistical 
knowledge. Permutation testing is available within some genetic software packages, including 
SOLAR. In paper IV and V permutation testing was performed to generate experiment-wide 
p-values. Observed genotypes were used and one third of the HUNT case/control cohort was 
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randomized as being affected. For example, for permutation number 1, individual number 1 
may be affected with genotype AA but for permutation number 2, individual number 1 may 
not be affected with genotype AA, and so on. In practice, for each of the 10,000 permutation 
tests there was a different set of preeclamptic women (~1.100) and a different set of control 
women (~2.200). The SNP genotypes were held constant, while the individuals coded as 
affected or not, changed. Then the normal measured genotype test was run. 
False discovery rate (FDR), developed by Benjamini and Hochberg351, attempts to control 
the proportion of false-positive results among reported statistically significant results. In other 
words, FDR is the expected proportion of false rejections within the class of rejected null 
hypotheses. Some advantages of applying a FDR include formal consideration of an 
alternative error rate, increased statistical power, and consistency of findings over differing 
number of inferences under consideration. In addition, this approach is less computationally 
intensive than permutation methods, and less conservative than the Bonferroni correction. As 
a result of this, FDR yields more power to detect genuine positive effects. A FDR of 5% was 
used in paper II.
The “gold standard” for identifying and eliminating false positives from the true association 
signals is independent (technical and biological) replication.
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4 SUMMARY AND DISCUSSION OF PAPERS 
4.1 Paper I  
Genetic association of preeclampsia to the inflammatory response gene SEPS1. 
Selenoprotein S (SEPS1, also known as SELS and VIMP)352,353 is a newly discovered 
inflammatory response gene, which plays a crucial role in protecting the functional integrity
of the endoplasmic reticulum (ER) against potential metabolic stressors and deleterious 
effects of oxidative stress.353 This novel ER and plasma membrane-located selenoprotein 
participates in the processing and removal of misfolded proteins from the ER to cytosol where 
they are degraded. The transcription of the SEPS1 gene is induced by ER stress and 
inflammatory cytokines, and impaired expression of SEPS1 has been associated with the A 
allele of a polymorphism in the promoter region in SEPS1 (-105G>A).354 Genetic variation in 
SEPS1 was recently shown to be strongly associated with circulating levels of pro-
inflammatory cytokines (TNF-D, IL-6, and IL-1).354 It has been suggested that SEPS1 may be 
a crucial genetic link influencing the pro-inflammatory cytokine profiles observed in common 
human disorders influenced by inflammation such as atherosclerosis, diabetes mellitus and 
cancer.355-357 With respect to a genetic contribution to the inflammatory response seen in 
preeclampsia, most attention has been given to polymorphisms in the pro-inflammatory 
cytokine genes, arguing that cis-acting genetic regulation may be at play. The TNF-D gene 
has been the most widely studied, with some reports showing association of promoter 
polymorphisms with preeclampsia265,266,268 or eclampsia269 with as many other studies finding 
no association263,270-272,358. Conflicting association data has also been reported for IL-6271,359.
In paper I we aimed to test for a genetic association between SEPS1 and preeclampsia by 
genotyping the -105G>A promoter polymorphism in 1,139 preeclamtic cases and 2,269 
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controls identified from the HUNT2 study population. Our results showed that women with 
preeclampsia were 1.34 times more likely to have the GA or AA genotype (P=0.0039; odds 
ratio (OR); 95% confidence interval (CI) 1.09-1.64) under a dominant genetic model and 1.22 
times more likely to carry the A allele (P=0.023; OR 1.22; 95% CI 1.02-1.46) under an 
additive genetic model. (Both models were adjusted to account for maternal age and 
primiparity using multivariate regression analysis).  
Multiple disturbances, including ischemia reperfusion injury, can cause an accumulation of 
unfolded proteins in the ER triggering an ER stress response called the unfolded protein 
response (UPR).360,361 In preeclampsia, ischemia reperfusion injury to the placenta results in 
placental oxidative stress which is widely thought to be involved in the increased lipid 
peroxidation and endothelial cell dysfunction associated with the pathophysiology of 
preeclampsia.362,363 Evidence of ER stress is observed in situations of altered vascular 
reactivity such as atherosclerotic lesions, neurodegenerative disorders, and metabolic 
syndrome, and has been implicated in placental dysfunction.364,365 The involvement of ER 
stress in endothelial dysfunction/injury has been explored in heart disease, with relevance to 
myocardial ischemia, cardiac hypertrophy, heart failure and possibly atherosclerosis 
(reviewed in 366,367). From the existing research in this field it seems possible that ER stress 
response (or UPR) can mediate both protective and damaging effects in the heart, depending 
upon the context. The general view is that UPR during the initial phases of ER stress mediates 
induction and activation of protective genes and proteins, whereas continued ER stress 
activate the pro-apoptotic machinery.367 However, involvement of ER stress has not been 
extensively studied in preeclampsia or in the maternal vasculature. When protein folding is 
persistent or excessive, due the UPR being perturbed or not sufficient to deal with the stress 
conditions, apoptotic cell death is initiated.368,369 Increased placental apoptosis is a feature of 
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preeclampsia,363 and we therefore speculate that SEPS1 may contribute to preeclampsia risk 
via a role in the ER stress response to reduced placentation. 
It is widely accepted that inflammation plays an important role in preeclampsia.64,370
Circulating levels of many pro-inflammatory cytokines and their modulators have been shown 
to be elevated in preeclamptic women compared to normal pregnant women.154-164,371
Cytokine imbalance and elevated expression of the pro-inflammatory molecules is also 
evident in preeclamptic placentas.165-168 In this large case-control association study, we have 
for the first time demonstrated association of a polymorphism in the recently discovered 
inflammatory response gene SEPS1 and preeclampsia. Based on the observation of 
association between genetic variations in SEPS1 and circulating levels of pro-inflammatory 
cytokines,354 and the evidence obtained in paper I, one may now speculate if SEPS1 also 
contributes to the perturbed circulating levels of pro-inflammatory cytokines and other 
inflammatory markers, including C-reactive protein and calprotectin, that have been reported 
in women with preeclampsia.370,372
In conclusion, the A allele of the SEPS1 -105G>A polymorphism is a risk factor for 
preeclampsia in the Norwegian population studied, possibly due to the effect this allele has on 
expression of SEPS1 and thereby the ER stress/inflammatory response. 
4.2 Paper II   
Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and 
pre-eclampsia in a large Norwegian population-based study (the HUNT study).
Three independent and distinct genome-wide scans in families from Iceland, Aust/NZ and 
Finland have provided evidence for maternal susceptibility loci for preeclampsia on 
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chromosome 2, although at different positions.206,207,212 The Aust/NZ linkage signal was 
further resolved and strengthened to chromosome 2q22, by use of a variance components-
based linkage approach. In paper II we aimed to further explore the association between 
positional candidate genes on chromosome 2q and preeclampsia by genotyping SNPs within 
seven genes at this locus in 1,139 cases and 2,269 controls identified from the HUNT2-study 
population. Our results showed evidence for association between preeclampsia and SNPs 
within one of these positional candidate genes, the activin receptor type II A (ACVR2A) gene. 
In the Australian study ACVR2A was identified as a high priority positional candidate gene at 
the 2q preeclampsia QTL by fine mapping in combination with an objective positional 
candidate gene prioritization strategy.204,208 A bioinformatics assessment of the Australian 2q 
QTL prioritized ACVR2A as the top positional candidate gene and gene expression profiling 
in decidual tissues from preeclamptic and normotensive women identified ACVR2A was one 
of the most differentially expressed genes, exemplifying the importance of this gene.204
ACVR2A is a key receptor for the cell signaling protein, activin A, which has long been 
recognized as an important regulator of human pregnancy.373 Therefore, altered expression of 
ACVR2A has been proposed to influence activin A concentrations and action with 
consequences on trophoblast invasion311 and remodeling of the spiral arteries312. The 
Australian preeclampsia study also reported preliminary evidence of an association between 
three SNPs in the ACVR2A gene and preeclampsia in a family-based cohort.204
In addition to promoting trophoblast proliferation and differentiation311 and having a 
fundamental function during implantation and decidualization,312 activin A modulates 
placental hormonogenesis313 and uterotonin secretion314. Activin A, like most members of the 
TGF-E superfamily, has a broad range of physiological actions and roles during development. 
Nevertheless, one of the unique properties of activin molecules, that have emerged relatively 
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recently, is their involvement in inflammation and immunity. Activin modulates several 
aspects of the inflammatory response, including release of pro-inflammatory cytokines, nitric 
oxide production and immune cell activity (reviewed in 374). In preeclamptic women elevated 
levels of activin A have been observed,314-318,320,375-378 and the placenta has been suggested to 
be the main source of activin A in maternal circulation.379 However, activated monocytes and 
endothelium (both components of the preeclampsia syndrome) are also potential sources of 
activin A, which means that not all of the rise is necessarily derived from the placenta.380
Given that preeclampsia is characterized by systemic inflammation, it is not surprising that 
activin A is increased in established preeclampsia,318 and in some cases, particularly in 
women with an early onset disease, before the disease manifests itself.376 The existing 
evidence suggests that activin A is an anti- rather than a pro-inflammatory molecule.381 In 
addition, activin seems to be anti-angiogenic since it inhibits endothelial cell proliferation.382
There is modest in vitro evidence that activin A can suppress certain components of the acute 
phase response,383 likewise hypoxic culture of placenta explants inhibits rather than increases 
the production of activin A.384,385 A study of acute coronary syndrome also proposes a 
potential anti-inflammatory role of activin A.386 Recently, activin A has been suggested to 
have a significant function in inflammatory diseases387-389 and atherogenesis390,391. Similar to 
preeclamptic patients, elevated serum levels of activin A have been reported in patients with 
CVDs.386,392,393 Interestingly, down-regulated expression of ACVR2A has been shown in 
patients with unstable CVD, suggesting a dysregulated receptor expression.386 It is known that 
women with preeclampsia have an elevated risk of later life CVD394 and women with existing 
CVD risk profiles (e.g. chronic hypertension and obesity) have an elevated risk of developing 
preeclampsia.14,395,396 Thus, the hypothesis may be raised that the linkage between ACVR2A 
and preeclampsia may be ascribed to the role of activin A in endothelial activation and 
systemic endovascular inflammatory responses. It is not clear whether the increased activin A 
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concentration/reduced ACVR2A expression is a cause or a consequence of placental 
dysfunction. Thus, the activin pathway is a plausible biological candidate for a role in 
mechanisms perpetuating preeclampsia pathogenesis. 
4.3 Paper III  
Evaluation of COMT as a preeclampsia candidate susceptibility gene, assessed by 
genotyping of the Val158Met polymorphism and transcriptional profiling in decidual 
tissue.
Several candidate genes for preeclampsia have been studied, with inconsistent results. 
Therefore the specific causative genes involved in preeclampsia still remain to be identified. 
A recent study put forward that deficiency in catechol-O-methyltransferase (COMT) is 
associated with preeclampsia.397 COMT is a key enzyme in the degradation of both 
catecholamines and estrogens398 which are associated with hypertension (reviewed in 399,400). 
High- and low-activity variants of COMT, due to single base changes, have been 
discovered.401 One polymorphism with functional implications is a non-synonymous G to A 
base change, the COMT Val158Met polymorphism. The Met-allele of this polymorphism is 
associated with a three- to four-fold decrease in COMT enzyme activity,402 and several 
clinical conditions such as pain perception,401,403 psychiatric disorders,404-406 hypertension,407-
409 and heart disease410-412 have been reported to be associated with this single base change. 
Inspired by Kanasaki et al.’s hypothesis that COMT deficiency is associated with 
preeclampsia, and the recent discussion of the relevance of their mouse model for 
preeclampsia413 in humans, we aimed to evaluate COMT as a candidate susceptibility gene in 
women in paper III. This was done by examining the potential role of the functional COMT
Val158Met polymorphism by genotyping this SNP in 1,134 preeclamptic cases and 2,263 
controls identified from the HUNT2-study population. In addition, since the maternal-fetal 
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interface is a likely site for the abnormal mechanisms in the pathogenesis of preeclampsia,414
COMT gene expression in decidual tissues from preeclamptic (n=37) and normal pregnancies 
(n=57) was also investigated. Our results showed no association between the COMT
Val158Met polymorphism and preeclampsia, and no differential expression of COMT
transcripts in the decidual tissues from preeclamptic women and controls was found. 
COMT is not a positional candidate gene, i.e. it is not located within linkage regions reported 
in preeclamptic families, but rather a candidate gene selected on basis of its biological 
function. The generalized endothelial dysfunction resulting in vasoconstriction and end-organ 
ischemia is attributed in all of the clinical aspects of the maternal syndrome in preeclampsia. 
Recent experiments have strongly suggested that several soluble factors affecting the 
vasculature are probably elevated because of placental hypoxia in the preeclamptic women, 
indicating that upstream molecular defects may contribute to preeclampsia. The search for a 
unique circulating factor has resulted in identification of multiple factors of endothelial 
dysfunction, activation and oxidative stress. A promising factor fulfilling the expectations of 
the “mysterious circulating factor” was sFlt-1, as it linked the placenta with various features 
of the maternal endothelial dysfunction. Elevated levels of sFlt-1 have been observed in 
women with preeclampsia, but not in all of them. Thus, sFlt-1 alone is not capable of inducing 
a generalized endothelial dysfunction. In the recently published study by Kanasaki et al. it 
was showed that pregnant mice deficient in COMT (Comt-/-) developed multiple functional 
and structural features of a preeclampsia-like phenotype. The Comt-/- mice delivered preterm 
with higher wastage of fetuses and showed a higher BP and a higher urinary albumin 
excretion in comparison with wild-type mice. Elevated levels of HIF-1Į protein in the 
placenta and significantly increased sFlt-1 plasma concentrations in pregnant Comt-/- mice 
compared to controls were also observed.397 HIF-1Į elevation may lead to a shallow invasion 
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of trophoblasts into the spiral arteries and uterine wall, resulting in vascular defects, hypoxia 
and inflammation.415,416 Kanasaki et al. observed that administration of 2-methoxyestradiol 
(2-ME), a natural metabolite of estradiol that is elevated during the third trimester of normal 
human pregnancy, rescued the Comt-/- mice from the preeclampsia-like syndrome without 
toxicity. Levels of 2-ME vary throughout gestation, with extremely low levels early in 
pregnancy and increasing levels towards term.417,418 2-ME acts like a pro-oxidant and has 
direct involvement in redox-regulated signaling,413 thus the mouse model for preeclampsia 
used by Kanasaki et al. provided a link between redox-regulated signaling and human 
pregnancy pathology.397 Moreover, it is known that 2-ME degrades HIF-1Į,419,420 and since 
HIF-1Į is essential in angiogenesis this activity may inhibit angiogenesis. Lack of 2-ME, as in 
the Comt-/- mice, may result in stable HIF-1Į and thus, increased oxidative stress and 
vascular pathology. Due to this absence of 2-ME in Comt-/- mice, the relevance of this model 
for preeclampsia in humans has been questioned.413 Taken together with the additional 
potential role of HIF-1Į in inflammation421 and lipopolysaccharide-induced sepsis422 it has 
been suggested that stable HIF-1Į alone at late pregnancy could elicit the preeclampsia-like 
phenotypes in Comt-/- mice.413
Supporting their findings in mice Kanasaki et al. observed lower levels of placental COMT 
and circulating 2-ME in women with severe preeclampsia.397 However, their study groups 
were rather small with 6 cases/6 controls and 8 cases/13 controls, respectively. Our COMT
transcriptional profiling results in decidua basalis tissue, from a relatively large number of 
preeclamptic and control women (37 and 57, respectively), are inconsistent with the existing 
observations, thus we can only speculate about the cause of these divergent observations. 
Possibilities include, a different function of COMT in the placenta, which is of fetal origin, 
and decidua basalis, representing the maternal side, the mRNA level does not correlate with 
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protein levels, or the case groups of the previous studies397,423 are simply too small with 
insufficient statistical power. 
Hypertension is a major feature of preeclampsia, and studies have reported association 
between COMT SNPs, e.g. Val158Met, and BP in humans,407-409,424 but such an association 
has not been found in pregnancy-induced hypertension,425 suggesting that mechanisms 
underlying hypertension in the pregnant and non-pregnant state may differ. Finally, it should 
be addressed that BP regulation apparently differs in Kanasaki et al.’s mice and humans. An 
association between COMT and BP in non-pregnant women has been revealed.408 In contrast, 
BP did not differ between non-pregnant Comt-/- and wild type (Comt+/+) mice. 
To summarize, the results from our highly powered case/control cohort study does not support 
Kanasaki et al.’s hypothesis that an association between COMT/2-ME deficiency and 
preeclampsia is due to variations in maternal COMT genotype. However, since only one 
single polymorphism has been evaluated in the present study it may be too early to draw final 
conclusions about the role of this enzyme in development of preeclampsia. 
4.4 Paper IV  
The ERAP2 gene is associated with preeclampsia in Australian and Norwegian 
populations.
Several loci most likely to harbor maternal susceptibility genes have been identified 
(reviewed in 224) by examining the probability of co-segregating loci within a familial cohort. 
The original Aust/NZ genome-wide linkage scan data set207,208 has been re-analyzed with an 
approach allowing a more refined variance-components-based procedure utilizing a biological 
threshold model for the preeclampsia phenotype. Application of this efficient genetic linkage 
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analysis method resolved and the strengthened the chromosome 2 linkage signal to 2q22,204
and revealed two novel maternal preeclampsia susceptibility QTLs to chromosomes 5q and 
13q.209 In paper IV we aimed to identify the susceptibility gene(s) for preeclampsia at the 5q 
QTL by genotyping SNPs within positional candidate genes in both an extended Australian 
family cohort (The 74 Family Cohort) and our Norwegian case/control cohort. Positional 
candidate genes residing within the bounds of the 5q QTL were objectively prioritized using 
the same computer program as in paper II, described in Moses et al. (2006)204 and Johnson et 
al. (2007)209. We used this data along with knowledge on current and emerging concepts of 
the pathophysiology of preeclampsia327 to select 10 genes for further analysis. Three of the 
genes, corticotrophin releasing hormone binding protein (CRHBP) and two endoplasmic 
reticulum aminopeptidase genes (ERAP1 and ERAP2), presented an association with 
preeclampsia and are all plausible candidates due to their biological roles. When we 
accounted for multiple hypothesis testing and the non-independence of genotyped SNPs, the 
CRHBP and ERAP1 SNP associations were borderline (0.05dpcorr<0.10) whilst the ERAP2
SNP associations remained significant (pcorr<0.05) in both the Aust/NZ familial and 
Norwegian case/control cohorts. We may also have found evidence of allelic heterogeneity 
for SNPs with the ERAP1 and ERAP2 genes (puncorr<0.05) within the 5q preeclampsia 
susceptibility QTL in the Aust/NZ and Norwegian cohorts. 
The associated SNPs in ERAP2 are missense, population specific, independent of each other 
and could possibly be playing a functional role, although it is not obvious what effect these 
amino acid changes have on the activity of the ERAP2 enzyme. Bioinformatic prediction of 
the importance of the borderline associated ERAP1 and significantly associated ERAP2 SNPs 
and how these may affect the protein folding kinetics was performed. The reported ERAP1
and ERAP2 SNPs reside within regions most likely to affect the three-dimensional (3-D) 
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structure and function of the proteins. SNP variants in ERAP1 were predicted to have a benign 
effect on the ERAP1 protein, while SNPs in ERAP2 were predicted to damage the 3-D protein 
structure and function of the ERAP2 protein. One of the ERAP2 SNPs resides within a motif 
essential for the enzymatic activity.426
ERAP1 and ERAP2 are categorized into the oxytocinase subfamily of the M1 (metallo-type) 
zinc-dependent aminopeptidase gene family, and there is a 49% amino acid homology 
between these enzymes.426,427 A third oxytocinase subfamily member of the M1 zinc-
dependent aminopeptidase gene family, leucyl-cystinal aminopeptidase (LNPEP), is clustered 
with and shares ~43% amino acid homology with both ERAP1428  and ERAP2427. This family 
of enzymes cleaves the N-terminus of numerous proteins thereby enabling them to play an 
important role in a plethora of biological functions including protein maturation and protein 
stability, cellular maintenance, growth and development, and defense mechanisms.429 Of 
major relevance to preeclampsia are their roles in BP regulation, immune recognition and the 
inflammatory response during pregnancy. 
LNPEP has been identified as an important placental peptidase involved in regulating the 
peptide hormones oxytocin, vasopressin and angiotensins.430 Marked reduction in serum 
protease levels has been observed as preeclampsia progresses, and this may facilitate 
inadequate degradation of vasopressin and angiotensin II and thereby increase placental 
vascular resistance.430 ERAP1 and ERAP2 also play a key role in BP regulation via their 
involvement in the RAAS. The ERAP1 enzyme has been characterized to effectively cleave 
and inactivate angiotensin II in addition to converting kallidin to bradykinin in vitro.431
Angiotensin II is an integral link in the RAAS, a physiological system with a long and well 
implicated history with preeclampsia pathogenesis.432,433 The characterization of the ERAP2 
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enzyme identified the ability to cleave angiotensin III to angiotensin IV and the conversion of 
kallidin to bradykinin with no hydrolytic activity against oxytocin, vasopressin or angiotensin 
II.427 A previous genetic study investigating known and novel ERAP1 SNPs in a Japanese 
case/control cohort identified a significant association of a missense SNP with essential 
hypertension.434 This SNP was subsequently shown to reduce the enzymatic activity of 
ERAP1 in its efficiency to cleave angiotensin II to angiotensin III by 60% and the enzymes’ 
ability to convert kallidin into bradykinin by 70%.435
CRHBP is a placental peptide hormone which exhibits an inhibitory effect when bound to 
corticotrophin releasing hormone (CRH), a prominent regulatory hormone with a diversified 
role in female reproductive physiology. Circulating CRH influences embryo implantation,436
parturition437 and an integrated stress response.438 After the 20th week of gestation the amount 
of CRH produced by the syncytiotrophoblasts in the placental bed increases and is released 
into the maternal circulation.439,440 This increase coincides with a decrease in CRHBP levels 
in a normal health pregnancy,441 but this indirect relationship is exacerbated in complicated 
pregnancies such as preeclampsia.442
A critical component in the development of preeclampsia is a maladaptation of the maternal 
immune response to the developing fetal allograft. The recent reported association between 
the ERAP1 gene and the HLA class I mediated autoimmune disease ankylosing spondylitis 
adds another plausible role for ERAP enzymes in the etiology of preeclampsia.443 ERAP1444
and ERAP2427 are co-localized within the ER, and have complementary functions in HLA 
class I peptide presentation.445 These enzymes are involved in trimming of HLA class I ligand 
precursors.446 ERAP1 has a unique property of trimming N-extended antigenic peptides to 
eight or nine residues,447 thus producing epitopes that are bound to most HLA class I 
molecules.448 The elimination of ERAP1 in cultured cells444,447 or mouse knockout models449-
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451 have shown to either enhance, inhibit or have no effect on the presentation of trimmed 
peptides bound to the MHC class I molecules. During early human pregnancy non-classical 
(class I) HLA-C, -E, -F and -G antigens expressed by invading trophoblast cells at the site of 
placentation are involved in a maternal-fetal immunological interaction with decidual (NK) 
immune cells via the killer immunoglobulin-like receptors (KIR).370 This is thought to be 
crucial for the establishment of immune tolerance to the fetal allograft and successful 
placentation. Much attention has been focused on this interaction in preeclamptic pregnancies, 
arguing that unfavorable genotype combinations of both the HLA and KIR molecules may be 
at play.452 The possible involvement of genetic variation in ERAP1 and ERAP2 in this 
interaction is now of great interest. 
In a preeclamptic pregnancy there is an exacerbated systemic inflammatory response, 
resulting in increased levels of circulating pro-inflammatory cytokines. ERAP1 cleaves cell 
surface receptors for the pro-inflammatory cytokines IL-1 (IL-1RD), IL-6 (IL-6RD) and TNF 
(TNFR1), which subsequently down-regulates their signaling.453 Thus genetic variants in 
ERAP1 could therefore have pro-inflammatory effects through this mechanism in light of the 
increased circulating IL-6 levels during pregnancy (reviewed in 454) ERAP2 has a much more 
limited pattern of expression in tissues than ERAP1,427 and the molecular genetic or 
functional information pertaining to ERAP2 is limited. Thus, we can only speculate on its role 
in immunological pathways based on its high homology with ERAP1 and proposed 
divergence from a common ancestral gene.427
The vascular, immunological and inflammatory responses are considered important 
physiological mechanisms in preeclampsia pathogenesis. Although we did not find significant 
associations between LNPEP, ERAP1 and CRHBP and preeclampsia it would be premature to 
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exclude these genes as risk factors for preeclampsia due to their biological functions. In 
addition, LNPEP and ERAP1 are in physical proximity to ERAP2, and only three CRHBP
SNPs were efficiently interrogated. The significant ERAP2 association results observed in two 
independent cohorts discloses a novel maternal preeclampsia risk locus in a region of known 
genetic linkage to this pregnancy specific disorder. 
4.5 Paper V  
Identification of TNFSF13B as a genetic risk factor for preeclampsia: replication of 
association in Australian and Norwegian populations. 
By re-analyzing the original Aust/NZ genome-wide linkage scan data set,207,208 the 
chromosome 2 linkage signal was strengthened and resolved to 2q22.204 In addition, this 
analysis approach identified two novel preeclampsia susceptibility QTLs to chromosomes 5q 
and 13q.209 In paper V we aimed to identify the susceptibility gene(s) for preeclampsia at the 
13q QTL by genotyping SNPs within positional candidate genes in both The 74 Family 
Cohort and our Norwegian case/control cohort. Only one of the four genes selected for 
genotyping, the tumor necrosis factor ligand superfamily, member 13B (TNFSF13B), showed 
association with preeclampsia in the two independent cohorts. In fact, this association 
pertained to an identical SNP in TNFSF13B in both the Aust/NZ and Norwegian cohorts. Our 
combined cohort association analysis showed significant association with preeclampsia 
susceptibility (p=0.002), which remained significant also after correcting for the total 
experiment (p=0.047).  
Ligands and receptors of the TNF superfamily are involved in signaling pathways important 
during development and host defense, they also have crucial roles in the regulation of cell 
survival and death in immune tissues. TNFSF13B is among the non-apoptosis-inducing 
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ligands playing a vital role in immune responses, in both the adaptive455,456 and innate457
immune systems. Non-apoptosis-inducing ligands like TNFSF13B have also been suggested a 
role in conferring immune privilege.140,458 Studies have demonstrated that both TNFSF13B 
gene and protein are well expressed in cytotrophoblasts.459,460 The observation of expression 
of TNFSF13B in villous cytotrophoblasts and in addition placental mesenchymal cells 
suggests that this protein may drive placental development, cell differentiation and/or other 
functions in the human placenta.460 Expression of TNFSF13B has been suggested to navigate 
maternal leukocytes toward a favorable maternal immune response, being beneficial for the 
fetus, instead of a harmful one.459 TNFSF13B has also been proposed a role in angiogenesis 
based on the observation that TNFSF13B is absent in the blood vessel endothelium of 
abortion patients whilst it is detected in normal pregnant women.459 Angiogenesis is essential 
for normal placental development, and abnormal angiogenesis with insufficient remodeling of 
spiral arteries is a hallmark of preeclampsia. 
The associated TNFSF13B SNP is a rare intronic SNP. However, this does not detract from its 
potential in playing a functional role in disease pathophysiology.461-465 It is well known that 
SNPs within regulatory regions (such as regions for transcription factor binding sites, exon 
splicing enhancers, conserved regions, splice sites and 3’UTR microRNA binding sites) of the 
genome can affect gene transcription. In the recent years, several studies have shown 
association between intronic SNPs and various complex diseases and it has become evident 
that rare variants (variants with minor allele frequency less than 1%) may play an important 
role in complex diseases.222,466,467
In conclusion, The TNFSF13B protein may be of profound importance to reproductive 
success in women,459 and may serve as a potential factor bridging the angiogenic and non-
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cytotoxic response machineries at the maternal-fetal interface.468 The finding of the genetic 
association between the TNFSF13B SNP and maternal preeclampsia susceptibility in two 
independent populations implicates this gene as a novel preeclampsia susceptibility gene, and 
supports the hypothesis that this gene may be of profound importance for a variety of 
processes essential to a successful human pregnancy. The fact that TNFSF13B resides within 
a region previously shown to be in linkage with preeclampsia susceptibility strengthens the 
association result. 
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5 DISCUSSION 
5.1 Methodological considerations 
In the fall of 2005, when most of the genotyping in the Norwegian case/control cohort 
presented in this thesis was performed, the iPLEX Gold assay from Sequenom and the 
GoldenGate assay from Illumina were not yet launched. However, Applied Biosystems’ 
SNPlex assay was launched January 2004, and was therefore chosen. Our experience with the 
SNPlex assay is that it is sensitive, but not as robust as the high-throughput iPLEX Gold and 
GoldenGate genotyping assays launched in late 2005 and early 2006, respectively. 
Due to the high sensitivity of the SNPlex assay and the varying genotyping success rates 
(d82%, sometimes considered less than satisfying), we decided to replicate SNPs that showed 
nominal and borderline association with preeclampsia with the SNPlex technology using a 
different technology. Sequenom’s MassARRAY technology was available at the Centre for 
Integrative Genetics (CIGENE), a Norwegian genotyping service institution. With the iPLEX 
Gold genotyping assay we obtained very high genotyping success rates (t98.5%).
To genotype samples in the Aust/NZ family cohort Illumina’s GoldenGate assay was used. 
This assay is robust and gives high genotyping success rates. Both the iPLEX Gold and 
GoldenGate assays seem to be preferred to the SNPlex assay nowadays. In addition, both the 
Illumina and Sequenom platforms can be used for additional approaches such as gene 
expression analysis, methylation analysis and copy number variation analysis. Another 
advantage of the GoldenGate assay is that it allows a higher level of multiplexing than the 
SNPlex and iPLEX Gold assays. It should also be mentioned that Illumina is one of the two 
major vendors of high-throughput genome-wide SNP genotyping technology.  
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In conclusion, if I were to perform high-through put genotyping today, I would not have 
chosen the SNPlex assay. I would rather have chosen the GoldenGate or iPLEX Gold assay 
depending on the number of SNPs I were to genotype. 
5.2 Study design 
Study design is perhaps the single most important issue in the planning of any genetic study. 
When planning a genetic association study, one must consider four major components: 1) the 
disease or trait to be studied i.e. the phenotype, 2) the study groups, 3) the genetic markers to 
be typed (genotype), and 4) the analytic method to test for association between genotype and 
phenotype data. The feasibility, necessary sample size, statistical power of a study and 
statistical analysis of genetic association data depend critically on the study design. 
Accordingly, advice from statistical geneticists is most helpful before the study begins. The 
use of the latest “highly promising” new method – or new software implementation of a 
current method – cannot rescue a poorly designed study. 
5.2.1 Phenotype
Definition of the phenotype is crucial in designing any genetic study,469 especially an 
association study that intends to detect disease predisposing genes. Accurate phenotype 
definition (i.e. one that has high specificity) is necessary to minimize the number of genes that 
may affect risk of disease, and thus to increase the odds of finding these genes.470 Definitions 
of phenotype in complex diseases are problematic due to issues of heterogeneity, gene-
environment interactions, and gene-gene interactions.471 Complex diseases may have 
diverging clinical manifestations, different biological paths leading to disease diagnosis, 
differences in severity of symptoms, symptoms that may deteriorate over time, and 
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differences in disease penetrance may all contribute to disease heterogeneity.470,472,473
Metabolic syndrome (abdominal obesity, high serum triglycerides, low HDL cholesterol, high 
BP, high fasting blood glucose) and CHD (myocardial infarction, atherosclerosis, and sudden 
cardiac death) are two common examples of complex diseases that are clinically 
multifactorial and where each element may have its own genetic influence. Clinical 
heterogeneity, meaning variation in clinical characteristics such as asymptomatic versus 
symptomatic individuals, diagnostic classification schemes, age of onset, severity, family 
history, diagnosis being almost any combination of symptoms, also displays in most diseases 
of interest.470 In cases where there are no biochemical markers or tests for the disease of 
interest, the phenotype may be defined using subjective assessments. Either through the use of 
diagnostic criteria, or by satisfying a predetermined number of symptoms can lead to 
imprecision and heterogeneity in the phenotype.474 One can minimize heterogeneity by 
focusing solely on those satisfying certain criteria on the list. However, this may affect sample 
size and reduce statistical power. 
Diagnostic error (misclassification) can substantially reduce the power to detect an 
association between a trait and marker locus.475,476 Misclassification due to poorly defined 
phenotypes can make it impossible to detect a true association or to identify spurious 
associations stemming from biased classification of the phenotype or confounding of the 
phenotype.477 Heterogeneity of phenotype and its underlying component can also lead to 
misclassification of phenotype.477 Further, dichotomizing a continuous phenotype also leads 
to a loss of power. One can reduce the potential of misclassification by using standard 
phenotype definitions, medical records or consensus committee agreement for a valid 
diagnosis.477 Validity refers to knowing what is being measured and how accurately it is being 
measured.478 However, most phenotypes can be defined by more than one instrument. Use of 
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a variety of methods to assess and measure phenotypes, often referred to as measurement 
errors, adds variability in phenotype definition, and thus, contributes to variability to any 
genetic study.474
Preeclampsia in our Norwegian HUNT case/control cohort was defined according to the 
criteria given by National High Blood Pressure Education Program Working Group on High 
Blood Pressure in Pregnancy.40 These diagnostic criteria are similar to the criteria in the 1998 
guidelines from The Norwegian Society of Gynecology and Obstetrics (NGF) (BP140/90
mmHg and t0.3 g/L in a 24 hour urine sample or t1+ on a dipstick reading after 20 weeks of 
gestation).61 National (Norwegian) guidelines for the preeclampsia diagnosis for clinicians 
responsible for taking care of pregnant women were not established until 1995. From 1967-
1998, preeclampsia in the MBRN databank was registered by ICD-8 codes, whereas ICD-10 
codes were used from 1998. The registration in MBRN is based on the information in the 
scheme filled out by midwifes/clinicians at the Delivery ward. This implies that the diagnosis 
of preeclampsia may have been used based on the criteria recommended by MBRN or 
alternatively, based on the midwife’s/clinicians’ own interpretation of the clinical 
manifestations presented. This may represent a problem with regards to the phenotypic 
consistency of the preeclamptic women included in MBRN since both definition and 
diagnostic criteria for preeclampsia have changed over time, also in Norway. Definition has 
changed with the revisions of the ICD codes, while diagnostic criteria have changed with the 
guidelines given by NGF, at least for the last 14 years. In 1995 NGF defined preeclampsia as 
BP t140/90 mmHg or an increase of DBP t15 mmHg compared with mean BP values 
measured before 20 weeks of gestation and  proteinuria with t0.3 g/L in a 24 hour urine 
sample or t1+ on a dipstick reading after 20 weeks of gestation,57 whereas the criteria used 
today are more restrictive; BP t140/90 mmHg combined with proteinuria t0.3 g/L in a 24 
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hour urine sample or a t1+ on a dipstick reading measured on at least two occasions with a 4-
6 hour interval.63 The todays NGF guidelines also specify mild and severe preeclampsia. 
Since there were no written national guidelines before 1995, it is difficult to evaluate changes 
in diagnostic considerations that might have taken place in Norwegian hospitals from 1967 
(when MBRN was established) to 1995.
The importance of valid diagnoses when performing genetic studies has received increasing 
attention among researchers the last years. In accordance with this, we have started to validate 
the diagnosis of preeclampsia by using the hospital records for the women registered as cases 
in our HUNT cohort. The preliminary results show that approximately 90% of these women 
fulfill the diagnostic criteria (given by MBRN; BPt140/90 mmHg andt0.3 g/L in a 24 hour 
urine sample or t1+ on a dipstick reading after 20 weeks of gestation) used for preeclampsia 
in the presented work. In a different study we found that the majority of the cases that were 
not confirmed had increased BP, but they turned out to have no documentation of proteinuria 
in their hospital records (Vestrheim et al., in preparation). We assume that this is also the 
case in our HUNT case/control cohort. There is a possibility that the genetic associations 
observed in the present work would have been stronger if the genotypes of the approximately 
10% that did not fulfill our diagnostic criteria were removed from the analysis. It remains to 
have a closer look at this when the validation process is finished. 
After the genetic analyses were performed, we have also had a closer look at our control 
group to study if individuals included in the control group had suffered from conditions 
potentially disturbing the genetic comparisons between cases and controls. The control group 
has in the published papers presented in this thesis been described as normal healthy pregnant 
women. In fact, the control group was selected from the MBRN database as non-
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preeclamptic, implying that they were not necessarily completely normal. By looking closer 
to the information in the MBRN database, we have found that some women in the control 
group had suffered from viral or bacterial infections during pregnancy (n=40), others had 
experienced pregnancy related complications such as hemorrhage, anemia (n=98) or 
hyperemesis (n=144), while six women had diabetes mellitus. Therefore, the controls have 
been described as non-preeclamptic women in this thesis. However, we assume that the 
mentioned conditions, with the exception of diabetes mellitus, are not related to the genetics 
of preeclampsia.  
5.2.2 Study groups 
Selection of a population is an important issue when planning a genetic association study. 
Genetic homogeneous populations are preferred to populations with high heterogeneity, since 
heterogeneity of genetic backgrounds among individuals in association studies may lead to 
false positive or false negative results. It is also important to ensure that the cases and controls 
are drawn from the same population, in order to avoid population stratification. Population 
stratification or population structure is the presence of a systematic difference in allele 
frequencies between subpopulations, such as cases and controls, in a population due to an 
overrepresentation of an ethnic group among individuals in one of the groups and 
underrepresentation among individuals in the other group. In the scenario of population 
stratification a significant p-value obtained is likely to be a reflection of the allele frequency 
differences between the two groups rather than a true association with disease. To avoid 
population stratification one should measure association in well-mixed, outbred populations. 
Matching by geographical region and by any markers of ethnic origin (in the design or the 
analysis, or both) can reduce population stratification.192
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Sample size is a key determinant of quality in an association study.479 Calculating the actual 
sample size needed to find a true genotype-phenotype association under the study constraints, 
i.e. the power of a study, is an important part of the study design. How many subjects one 
needs for a well-powered analysis depends on the allele frequency of the genetic marker, the 
genotype relative risk (the allelic odds ratio), and the significance level (D-level). In addition, 
one should consider the inheritance model (dominant, recessive or additive) and the measure 
of the overall disease risk in the population. 
The preeclamptic cases and the controls in the work presented in this thesis were 
retrospectively identified from a ethnically homogeneous population, with less than 3% non-
Caucasians, regarded as a representative of Norway with regard to geography, economy, 
industry, age distribution, morbidity, and mortality. Among the approximately 65,000 
participating in the HUNT2 study we were able to identify 1,139 women registered with at 
least one preeclamptic pregnancy in the MBRN with a biological sample available from the 
HUNT biobank. A group of over 1,000 preeclamptic cases is considered rather large in 
case/control studies of candidate genes. Other published case/control studies from Great 
Britain227 and Finland480 included 657 and 248 preeclamtic cases, respectively. Due to the 
ethnic homogeneity and large sample size we consider our Norwegian case/control cohort 
well suited for genetic epidemiologic studies. Another advantage Norwegian researchers have 
is the access to data from good quality health registers, such as the MBRN. 
Subgroups of preeclampsia. In our efforts to identify subsets of preeclamptic women 
classified cases according to clinical characteristics related to the syndrome; i.e. the parity of 
women developing preeclampsia (first pregnancy or subsequent pregnancies) was registered 
and if preeclampsia developed in one of more pregnancies and if preeclamptic symptoms 
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developed early (34 weeks of gestation) or late (close to or at term) in pregnancy. Among 
our cases, 1003 women were registered with only one preeclamptic pregnancy (606 in their 
first pregnancy and 397 in a later pregnancy), whereas 136 women had experienced 
preeclampsia in more than one pregnancy (recurrent preeclampsia). Classification of cases by 
mild or severe and by early or late onset preeclampsia was not done, since this was only 
possible for the cases who delivered after 1998 when MBRN changed their routines and 
introduced a new registration form for deliveries. But, it turned out that the subgroups based 
on these criteria were too small to have the statistical power required for genetic comparisons. 
However, the research value of subgroups of significant size should not be underestimated. 
Preeclampsia is a condition likely to be a result of heterogeneous causes of both maternal and 
placental/fetal derivation, potentially involving several separate pathophysiological pathways. 
There is also a discrepancy in maternal outcome related to having preeclampsia as a 
multipara, as a recurrent event and by early onset of the disease. It has been shown that 
women experiencing early onset preeclampsia is more likely to have preeclampsia in a 
subsequent pregnancy.481 Recurrent and early onset preeclampsia are associated with a higher 
risk of developing CVD later in life than experiencing this disease in first pregnancy at 
term.19,20,482 These observations suggest that maternal constitutional factors are extensively 
involved in this subtype(s) of preeclampsia and that immune maladaption is not the solely 
causal factor. The recurrent and early onset preeclampsia are likely to be strongly associated 
with inflammation, oxidative stress and genetic susceptibility, whereas risk of preeclampsia 
among primiparas is more likely to represent the immune maladaption hypothesis. In 
conclusion, one should try to select the cases that seem most appropriate based on what the 
focus of the study is. 
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5.2.3 Genotype
Genotyping involves errors, although to a much lesser degree than phenotype measurement. 
There will never be a perfect system for genotyping, or for detecting and correcting 
genotyping errors. Even with the best methods, some assays will be unreliable. Genotyping 
errors can be generated by different causes, there are errors linked to the DNA sequence itself, 
errors that are due to low quality or quantity of the DNA, biochemical artifacts and human 
factors. A mutation close to a marker can generate a genotyping error if this flanking 
sequence is involved in the marker-detection process. Genotyping errors are also promoted by 
low DNA quantity and/or quality. Extreme dilution of or degradation of the DNA results in a 
low number of target DNA molecules, favoring allelic dropouts (i.e. only one of the two 
alleles present at a heterozygous locus is amplified), false alleles (allele-like artifact generated 
by PCR) and increased risk of contamination.483 An example of a biochemical artifact 
potentially generating genotyping error is the “+A artifact” which is a result of the Taq 
polymerase adding a non-template nucleotide (usually adenine (A)) to the 3’ end of the newly 
synthesized strand at the end of the elongation step of a PCR.484,485 This creates an artifactual 
band/peak on a gel/trace readout, respectively. The relative proportions of the true fragment 
and the +A artifactual fragment are very sensitive to the sequence of the 5ƍ end of the primer 
used in the genotyping assay, but also to PCR conditions and to the long elongation times that 
promote the +A artifact. In such a context, this biochemical artifact represents an important 
cause of genotyping error. Human factors have been identified as the main cause of 
genotyping errors in the few studies designed to analyze the precise causes of genotyping 
error.486 In one study on microsatellites human factors (scoring, data input, sample mix-up, 
pipetting error or contamination) were responsible for about 93% of the errors.487 Scoring 
errors might be an important issue in both manual and automated/semi-automated scoring of 
fluorescence profiles.488,489 Allele calling has also been identified as a potential problem in 
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SNP studies.490 However, the risk of human scoring error strongly depends on the quality of 
the data. When an estimated genotype is not the true genotype it is called a genotype 
misclassification error. The misclassification rate of genotypes depends on the type of marker 
(microsatellite or SNP), the specific marker being typed, the quality of the DNA sample and 
the protocol and experience of the laboratory staff among other factors. Misclassification rates 
of SNPs are much lower than of microsatellites and occur in less than 1% of genotypes with 
the current technology.491 It may be problematic to type rare variants since these are difficult 
and sometimes impossible to distinguish from genotype errors and mutations in population 
studies.
Random genotyping error reduces the power to detect true case/control differences,492,493 by 
each 1% rise in genotyping error an increase of the sample size by 2–8% might be required to 
maintain constant type I and type II error rates.492 Although random genotyping errors have 
an effect on power, systematic genotyping errors are of greater concern. In case/control 
studies DNA samples may be processed in batches due to a large number of samples and that 
storage and subsequently genotyping of different sample sets are performed on separate 
plates. Cases and controls should be ascertained and genotyped together in order to ensure 
that differences in genotypes are not due to variation in processing the samples and variations 
between batches. It is also important that quality controls are in place for accurate genotype 
calling.
Until now only a few studies have dealt with the genotyping error issue related to association 
studies. Thus, the effect of genotyping errors remains largely unknown in this 
field.483,488,494,495 Lack of studies and complexity of the problems are possible explanations for 
the delay in establishing strict standards to promote data quality in association studies. 
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However, researchers have become aware about the occurrence of genotyping errors and their 
potential effect, thus it is likely that increasing attention will be paid to these difficulties when 
designing experimental protocols and publishing results. 
In our SNPlex genotyping we used 384 well plates, some with only cases and some with only 
controls, but there were plates also mixed with case and control samples. However, in the 
genotyping processing there were always both plates with cases and controls being treated at 
the same time. It is admitted that handling cases and controls on separate plates might have 
introduced errors, thus in our replication with the iPLEX Gold assay we ensured that both 
cases and controls were present on each plate. Also in the TaqMan genotyping (paper III), 
both cases and controls were present on each plate.  
With the SNPlex genotyping assay, we observed that samples with low DNA concentrations 
(that had to be concentrated prior to genotyping processing) showed poorer genotyping results 
than those with high start concentration. To minimize the effect of poor genotype clustering, 
sample wells of poor quality were first identified and subsequently removed prior to 
genotyping clustering and statistical analysis.  
5.2.4 Analytical methods 
Study design and analysis methods are tied to each other, and the type of data to collect 
(family or population-based) predetermine what analytical method to test for association 
between genotype and phenotype data that can be used (linkage or association). There are 
many different analytical methods available, however the researchers must consider which 
one is best in their study situation.
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5.2.5 Summary 
The inconsistency of results in preeclampsia association studies is likely due to several 
causes:
1) there is no universal definition of preeclampsia and inclusion criteria are often 
inconsistent in terms of underlying chronic conditions, parity and ethnicity
2) the maternal genotype and the fetal (paternal) genotype is likely to have a 
predisposing effect,
3) association studies with small sample sizes often miss small-to-moderate effects 
because of lack of adequate statistical power and observed effects may be 
overestimated. It has been postulated that the main reason for the poor success in 
complex diseases with any approach is the lack of attention to experimental design.352
Genotyping errors are also a possible source of bias in association studies.
Due to the lack of replication of initial findings in association studies, a strict phenotype 
definition is important. However, there is mounting evidence that natural selection has shaped 
a considerable part of the differentiation observed between different ethnic subsets. 
Differential frequency of the trait-causing genetic variants and/or interactions with varying 
environments in different populations makes it difficult to detect uniform effects in all 
populations. If this is a major feature in our genomic evolution then it will be even more 
important to examine and compare a variety of different ethnic groups in future genetic 
studies in order to reveal the genetic basis of preeclampsia. This will also be the case for other 
common complex diseases or traits. 
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5.3 Interpretation of results 
Perturbations within vascular, immunological and inflammatory pathways constitute 
important physiological mechanisms in preeclampsia pathogenesis. All the genes reported 
associated with preeclampsia in the papers presented in this thesis pertain to one or more of 
these pathways, and it seems like most of them are pleiotropic. Abnormal placental 
development, predisposing maternal constitutional factors (such as diabetes, hypertension, 
obesity, and hyperlipidemia), oxidative stress, immune maladaption and genetic susceptibility 
are categories of suggested underlying causes of preeclampsia (reviewed in 64-66).
5.3.1 Selenoprotein S (SEPS1) 
Selenoproteins play crucial roles in regulating ROS and redox status in a wide variety of 
tissues and cell types, including those involved in innate and adaptive immune responses.496-
498 Thus selenoproteins such as SEPS1, obviously pertain to both the immunologist’s and 
vascularist’s views. Given the known association of SEPS1 with inflammation, we 
investigated the effect of a known functional genetic polymorphism in SEPS1 on the risk of 
preeclampsia (paper I). A significant association was found between this polymorphism and 
increased risk of preeclampsia. This finding supports the hypothesis of Curran et al. 
suggesting that SEPS1 might be involved in the pathogenesis of many common complex 
diseases influenced by inflammation. Replications in independent population cohorts with 
large sample size are needed to clarify the role of the SEPS1 -105G>A promoter 
polymorphism on the risk of preeclampsia. 
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5.3.2 Activin receptor type II A (ACVR2A) 
In paper II we report association between genetic polymorphisms within the activin receptor 
ACVR2A and preeclampsia. Activin receptors modulate signals for the multifunctional 
cytokine activin A, which is expressed in a wide range of tissues and cells. Endothelial cells, 
smooth muscle cells and macrophages in vascular tissue have been shown to express activin 
receptors,390 and activin A has an established role in endothelial functioning and vascular 
homeostasis. Several studies suggest that activin A is involved in pathogenesis of diseases 
influenced by inflammation.387-389 It has been proposed that activin A is an element of the 
early innate response to danger and that it is a defensive or regulatory component of the innate 
immune response.499 In light of the pleiotropic effects of activin A, pertaining to both the 
vascular and immune systems, ACVR2A is a plausible candidate gene for preeclampsia from 
both the vascularist’s and the immunologist’s point of view. Altered ACVR2A binding may 
result in endothelial dysfunction triggering systemic inflammation, hypertension, proteinuria 
and edema. In addition, altered expression of ACVR2A and binding to activin A may result in 
abnormal development of placenta.311,312
Recently, the Australian research group has comprehensively re-sequenced the entire coding 
region of the ACVR2A gene and the conserved non-coding sequences.321 This resulted in 
identification of 9 novel SNPs, which were genotyped together with 36 additional ACVR2A
SNPs in 480 individuals from 74 Aust/NZ preeclampsia families. Associations between five 
ACVR2A polymorphisms, three being novel, and preeclampsia were observed (p<0.03). 
However, after correction for multiple hypothesis testing, none of these associations reached 
significance (p>0.05). Based on this data it remains unclear what role, if any, ACVR2A
polymorphisms play in preeclampsia risk, at least in the Aust/NZ families. It remains a 
possibility that the observed association with preeclampsia in the Norwegian cohort is due to 
83
LD between ACVR2A SNPs and a functional variant close to this gene. LD patterns for the 
SNPs tested in the two studies are shown in Figure 9. The inconsistent results may also be due 
to allelic heterogeneity between the Aust/NZ and Norwegian populations, or alternatively, the 
sample size of the Australian study may be too small. In conclusion, replication in sufficiently 
powered studies is needed to further clarify the role of ACVR2A in preeclampsia risk.  
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5.3.3 Catechol-O-methyltransferase (COMT) 
As a protein involved in BP regulation and oxidative stress, via its metabolite 2-ME, COMT 
represents the vascularist’s view. We have shown that the COMT Val158Met polymorphism 
is not associated with preeclampsia risk (paper III), but we cannot exclude that this enzyme 
plays a role in the development of preeclampsia. It has been reported that the Val158Met 
polymorphism alone cannot account for the observed variation in COMT activity. A different 
SNP (rs4818) in the haploblock has been suggested to account for a greater variation in 
COMT activity compared to the Val158Met polymporphism.288 However, the fact that the 
COMT locus has not been reported as a preeclampsia QTL further disagrees with the 
hypothesis of Kanasaki et al.. In order to clarify the role of COMT as a genetic risk factor for 
preeclampsia development, additional COMT polymorphisms have to be investigated in a 
large number of cases and controls. 
5.3.4 Endoplasmic reticulum aminopeptidase 2 (ERAP2)  
With the key role ERAP2 has in BP regulation via its involvement in RAAS, this enzyme 
obviously represents the vascularist’s view. In addition, aminopeptidases, such as ERAP1 and 
ERAP2, have important roles in protein maturation and protein stability in addition to cellular 
maintenance, growth, development, and defense mechanisms.429 It is likely that ERAP2 plays 
a role in immunological pathways based on it’s highly conserved extracellular domain with 
ERAP1 and proposed divergence from a common ancestral gene.427 Thus, ERAP2 may also 
fit in with the immunologist’s view. 
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In paper IV we report significant association between ERAP2 SNPs and preeclampsia risk in 
two independent populations; the Norwegian and the Aust/NZ. However, the associated SNPs 
seem to be population specific (Figure 10).  
An alternative explanation for the divergent SNP associations in the two populations might be 
that we have observed a false positive association(s). On the basis of the physical proximity 
between ERAP2, ERAP1 and LNPEP it is possible that there are other functional genetic 
variations in ERAP1 or LNPEP that are in LD with the significant ERAP2 SNP associations. 
Deep re-sequencing of all three genes followed by further association analyses in the 
Australian family and Norwegian case/control cohorts will be required to resolve this. 
Independent replication in other populations is also encouraged in order to clarify the role of 
ERAP2 on preeclampsia risk. 
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5.3.5 Tumor necrosis factor ligand superfamily, member 13B (TNFSF13B) 
Our observed association between TNFSF13B and preeclampsia (paper V) suggests that the 
influence of the maternal immune system is significant. The observation appears consistent 
with the theory that maternal-fetal immune maladaption is central in the pathogenesis of the 
preeclamptic syndrome. A potential role of TNFSF13B as an angiogenic factor has also been 
suggested,459 in that case it potentially also represents the vascularist’s view. Furthermore, 
TNFSF13B has recently been suggested a role in implantation, cell differentiation and 
placental development/function459,460 via its expression by maternal decidual stromal cells and 
trophoblasts.
Although we observed association between preeclampsia and an identical TNFSF13B SNP in 
two independent populations, we cannot rule out the possibility that there exists other as yet 
unidentified rare sequence variant(s) in LD with the associated SNP that are the actual causal 
mutations. Deep re-sequencing in, and around, the TNFSF13B gene in our preeclampsia 
cohorts will be required to enumerate and prioritize all variation prior to formal functional 
evaluation. Very recently, we have in close collaboration with the Australian researchers 
performed deep re-sequencing, and are currently planning further association analyses in both 
the Aust/NZ family and Norwegian case/control cohorts. We also encourage replication in 
other independent populations. 
Finally, due to the observation of trophoblasts expressing TNFSF13B it would be interesting 
to look into how fetal TNFSF13B genotype, alone or in combination with maternal genotype, 
influences preeclampsia development. 
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5.4 Inflammation, preeclampsia and other common complex diseases 
Inflammation has a role in and often precedes the onset of many common complex diseases, 
including cancer, atherosclerosis, diabetes and Alzheimer disease. It has been suggested that 
genetic factors have a key role in inflammation, and the search for genes and genetic variants 
of relevance is a strong ongoing research activity. Normal pregnancy is characterized by a 
mild, systemic inflammatory response, but the inflammatory manifestations are much more 
vigorous in preeclampsia with endothelial dysfunction and activation, together with increased 
levels of oxidative stress markers and pro-inflammatory cytokines.500 Accordingly, it has been 
hypothesized that any factor that would increase the maternal inflammatory response to 
pregnancy would predispose to preeclampsia.75 Abnormal maternal inflammatory responses 
seem to favor development of preeclampsia; i.e. increased preeclampsia risk has been 
reported in women with inflammatory cytokine267 or cytokine receptor276 gene 
polymorphisms. In accordance with this, we have observed increased frequency of other gene 
variants involved in inflammation, i.e. the SEPS1501 and the ACVR2A322 genes in HUNT2 
preeclampsia cases. 
SEPS1 is strongly suggested to be involved in ER stress,279 which is likely to induce systemic 
inflammation.502 ER stress has been associated with a wide range of diseases including stroke, 
cardiac disease, diabetes, cancer, neurodegeneration, bipolar disorders, muscle degeneration 
and others.503 Some of these diseases are also associated with preeclampsia, e.g. CVD and 
diabetes. The number of studies investigating the effect of SEPS1 polymorphisms on the risk 
of different diseases influenced by inflammation is increasing. A recent study of the effect of 
SEPS1 SNPs on the risk of cardiovascular disease (including both coronary heart disease 
(CHD) and ischemic stroke (IS)) in Finnish cohorts is supportive. This study showed that 
genetic polymorphisms in SEPS1 is likely to increase the risk for coronary heart disease and 
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ischemic stroke, particularly in females.504 Suggestive associations of SEPS1 SNPs were also 
seen with the known cardiovascular risk factors body mass index (BMI) and waist-hip 
ratio.504 Interestingly, secreted SEPS1 has been associated with very low density lipoprotein 
(LDL) fraction of the serum suggesting a role also in the lipid metabolism.356 Thus, SEPS1
might be a genetic link between preeclampsia and CVD and diabetes, since BMI, waist-hip 
ratio and abnormal lipid profiles are associated with increased risk of all these conditions. 
Other studies of SEPS1 polymorphisms on the risk of variety of inflammatory diseases have 
also recently been reported, however with inconsistent results (Table 4). 
Table 4:  Studies performed to date (April 2009) on SEPS1 polymorphisms and a variety 
of diseases influenced by inflammation. 
Publication Disease Sample 
size 
SNPs Association 
(+/-)
Population
Alanne et al. 2007504 Cardiovascular 
CHD
IS
999 
1,223 
rs8025174 
rs28665122 
rs4965814 
rs4965373 
rs9874 
rs7178239 
+a
÷
÷
÷
÷
+b
Finnish 
Hyrenbach et al. 2007505 Cerebrovascular 
IS, cervical artery 
dissection  
IS, non-cervical 
artery dissection  
260 
295 
rs28665122 ÷ German and  
Italian 
Seiderer et al. 2007506 IBD 359 rs28665122 ÷ German 
Moses et al. 2008501 Preeclampsia 1,139 rs28665122 + Norwegian 
Martinez et al. 2008507 Autoimmune
inflammatory 
RA
IBD
T1D
592 
674 
311 
rs11327127 
rs28665122 
rs4965814 
rs12917258 
rs4965373 
rs2101171 
÷
÷
÷
÷
÷
÷
Spanish 
Shibata et al. 2009508 Gastric cancer 268 rs28665122 + Japanese 
a – this SNP was associated with increased risk of CHD in females only. 
b – this SNP was associated with increased risk of IS in females, and in females combined with males. 
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No association with the SEPS1 -105G>A promoter polymorphism on the risk of 
cerebrovascular disease (including IS because of cervical artery dissection and IS of non-
cervical artery dissection origin) has been observed, but the sample size of the groups studied 
were small.505 Lack of association with SEPS1 polymorphisms on the risk of autoimmune 
inflammatory diseases, such as rheumatoid arthritis (RA), inflammatory bowel diseases (IBD) 
(including both Crohn’s disease and ulcerative colitis) and type 1 diabetes (T1D), was also 
recently reported,506,507 but as for the cerebrovascular disease study, the sample sizes were 
small. The most recent study of the SEPS1 -105G>A promoter polymorphism reports 
influence on susceptibility to gastric cancer in a Japanese population.508 This study is also a 
small one, and further studies with a greater number of cases will be needed to fully address 
the importance of these SEPS1 genetic polymorphisms on the risk for inflammatory diseases 
and gastric cancer. 
As a key receptor for activin A, a critical mediator of inflammation and immunity, ACVR2A 
is likely to be of importance in inflammatory diseases. Our observation of association 
between ACVR2A SNPs and preeclampsia confirms this suggestion. To my knowledge there 
are no association studies published on ACVR2A SNPs and diseases associated with 
preeclampsia, such as cardiovascular diseases. However, aberrant gene expression (mRNA) of 
ACVR2A has been observed in unstable angina patients.386 And it has been hypothesized that 
dysregulated expression of activin A and its receptors could contribute to atherogenesis and 
plaque destabilization.386 Association studies of ACVR2A SNPs in large samples of common 
complex diseases influenced by inflammation are needed in order to clarify the role of this 
gene on the risk of these diseases.
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It is possible that common genetic predisposition may underlie preeclampsia and diseases 
associated with preeclampsia, such as CVD. Thus, it is likely that new knowledge gained 
about genes/genetic mechanisms important in preeclampsia also will provide insight relevant 
for understanding the development of cardiovascular diseases in women. 
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6 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
Taken together, the results presented in this thesis confirm that preeclampsia is a complex 
genetic disease, involving different biological processes previously ascribed a role in the 
pathogenesis of this disease; inflammation, immune maladaption, abnormal placental 
development. The papers presented in this thesis show that maternal genes may contribute to 
the predisposition to all these processes. In this regard it is not surprising that simple clinical 
indicators are ineffective in identifying preeclamptic women, since the condition is likely to 
be a result of heterogeneous causes of both maternal and placental/fetal derivation, potentially 
involving several separate pathophysiological pathways. There is also a discrepancy in 
maternal outcome related to having preeclampsia as a multipara, as a recurrent event and by 
early-onset of the disease. This realization has led to the formulation of a new conceptual 
framework suggesting that a combination of markers (biochemical and/or biophysical) may 
be required to conduct comprehensive risk assessment for the syndrome. 
To further elaborate the genetic contribution to development of preeclampsia one should 
focus on different preeclampsia phenotypes. Although we are able to classify our HUNT2 
preeclampsia cases in different preeclampsia subgroups, we need to increase the sample sizes 
before performing association studies of significance. Increasing the sample sizes can be done 
by adding preeclampsia cases from the Norwegian Mother and Child Cohort Study 
(MoBa).509,510 The MoBa cohort is an ongoing pregnancy study (started in 2001), with the aim 
of comprising 100,000 pregnancies. The purpose of the MoBa study is to find causes of 
diseases among mothers and children. A highly prioritized focus of attention for the MoBa 
cohort is genetic factors, as well as the potential interplay between genes and exposure 
(environmental factors). With the prevalence of preeclampsia among Norwegian pregnant 
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women,511 approximately 2,550 preeclamptic pregnancies will be found among the 90,000 
included at present in the MoBa cohort. 
Investigators studying complex disorders are increasingly turning to integrated approaches, 
which must include an appreciation of underlying biological processes, but can also utilize the 
power of genome-wide screening, RNA microarray technology, proteomics and 
bioinformatics to generate novel hypotheses. One by one these resources may generate 
hundreds of candidate genes. Combining two or more of the resources seem to improve the 
yield in reducing the number of candidate genes and in enabling us to focus on the most likely 
candidate genes.512,513 Figure 11 gives an overview of resources being available to my 
research group and ongoing or planned studies, and how these can be combined to improve 
the understanding of genetic susceptibility of developing preeclampsia. 
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Due to dramatic increases in high-throughput sequencing for detecting sequence variants, as 
well as microarray technologies for gene identification, pathway analysis, and mapping of cis
and trans regulatory elements the rate of gene discovery is expected to accelerate. These 
resources will greatly facilitate the identification of genes underlying the hundreds of QTLs 
mapped for complex diseases and phenotypes. Thus, many of the bottlenecks associated with 
traditional mapping and cloning approaches might be overcome. Although the capacity and 
costs of the technology are no longer significant bottlenecks, the availability of large 
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populations with consistent and well-characterized descriptions of clinical traits, or multiple 
relevant phenotypes, are challenges to overcome. Large efforts have been spent and are 
underway to develop large population-based biobanks. Over 100 biobanks with a sample size 
of more than 10,000 subjects have been completed or are currently being conducted. (P3G 
Observatory: http://www.p3gobservatory.org/) Some examples of large-scale cohort biobanks 
aiming to investigate the genetic basis of multiple important diseases are the Icelandic 
biobank deCODE, The UK Biobank, the CARTaGENE in Canada, the Estonian Genome 
Project and the Kadoorie Study of Chronic Disease in China. The HUNT biobank is also an 
example of large-scale population-based cohort biobank. There are also disease-specific 
biobanks, which often contain tissues relevant for the disease of interest in addition to genetic 
material. In preeclampsia research, birth cohorts (biobanks) are valuable, such as The 
Norwegian Mother and Child Cohort Study (MoBa) and the Danish National Birth Cohort.
The most widely used contemporary approach to relate genetic variation to phenotypic 
diversity, GWAS,514 is an investigation of genetic variations across the entire genome aiming 
to identify genetic associations with traits, or the presence or absence of a disease or 
condition. The GWAS approach is hypothesis-free and represents an unbiased yet fairly 
comprehensive option that can be attempted even in the absence of convincing evidence 
regarding the function or location of the causal genes.515 Results of these studies have 
identified several common variants across the genome influencing common complex traits 
over the past 2 years and have rapidly and substantially increased the understanding of the 
diverse molecular pathways underlying specific human diseases (published GWAS catalogue 
can be viewed at http://www.genome.gov/gwastudies/). Although there has been an 
increasing enthusiasm about GWAS and many believe that these studies are the answer to 
many scientific needs, there are also those who feel that these studies are fatally flawed 
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endeavors that are draining research funding. It has become clear that, GWA studies have 
several limitations; 1) the causal variant is rarely revealed, and there is great difficulty to 
identify the functional basis of the link between a genomic interval and a given complex trait, 
2) SNP associations identified in one population are often not transferable to other 
populations, 3) they do not capture information about rare variants and have limited statistical 
power to detect small gene-gene and gene-environment interactions. Despite the limitations of 
GWA studies, there is no doubt that this approach may identify novel candidate pathways and 
genes involved in complex diseases. The knowledge gained has improved the understanding 
of GWA studies, and there has been some useful discussions on design, implementation, best 
practice and interpretation of such studies.514 In particular, the difficulties of replication has 
been an issue since independent replication has been considered the gold standard for 
validating GWAS findings.516 It should be admitted that this is still an evolving field, and it is 
likely that the challenges that remain will be solved. In my opinion it is just a matter of time. 
In addition, one should bear in mind that GWAS is a study at the DNA level, and further 
studies at DNA, RNA and protein level might be needed to work out how the gene(s) 
contribute to the disease or trait. It has recently been suggested that because of the 
introduction of novel high-throughput, low-cost sequencing methods, sequencing and 
genotyping will soon converge. Finally, the functional relevance of identified variant(s) 
should be confirmed by in vivo or in vitro studies.
To my knowledge there are yet no published GWAS on preeclampsia. However, we and other 
groups are currently planning such studies. In collaboration with Australian, American and 
British investigators we have applied to National Institute of Health (NIH) for funding of 
GWAS in Norwegian preeclamptic women and control women, including the validated cases 
in our HUNT case/control cohort and cases identified in the MoBa. In addition, a Norwegian 
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preeclampsia family biobank is under establishment. Approximately 150 families with 
increased incidence of preeclampsia have been identified. Thus, this family biobank has the 
potential to become one of the largest in the preeclampsia field. And in addition to collecting 
blood for DNA analyses, we also collect blood for RNA and protein analyses. 
With the increased knowledge about genetics underlying complex diseases, it is interesting 
that one gene or genetic variant may be associated with multiple seemingly distinct diseases. 
This has led to the concept of the “diseaseome”,517 which maps a network of how different 
genes and pathways connect to various diseases. Figure 12a517 shows a disease gene network 
where all known disease genes in the human genome, by May 2007, were included. A human 
disease network giving a global view of all known genetic disorders, by May 2007, has also 
been constructed (Figure 12b)517. However, these maps are far from complete, and with the 
explosion of all the novel genes or genomic loci identified during the last 2 years, these maps 
need to be updated. 
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ABSTRACT 23
The suspected aetiology of pre-eclampsia is complex, with susceptibility being 24
attributable to multiple environmental factors and a large genetic component. 25
Although many candidate genes for pre-eclampsia have been suggested and studied, 26
the specific causative genes still remain to be identified. Catechol-O-27
methyltransferase (COMT) is an enzyme involved in catecholamine and estrogen 28
degradation, and has recently been ascribed a role in the development of pre-29
eclampsia. In this present study we have examined the COMT gene, by genotyping the 30
functional Val158Met polymorphism in a large Norwegian case/control cohort 31
(ncases=1,134, ncontrols=2,263). In addition, the expression of the COMT gene in 32
decidual tissues from pre-eclamptic (n=37) and normotensive (n=57) pregnancies was 33
compared. No association between the Val158Met polymorphism and pre-eclampsia 34
(p>0.33) was observed, and no difference in decidual COMT mRNA expression levels 35
was observed between pre-eclamptic and normotensive women (p>0.7). The Met-36
allele of the Val158Met polymorphism is associated with a three- to four-fold 37
reduction in COMT activity, and thus, the observations obtained in the current study 38
do not support the suggested role of COMT as a maternal genetic risk factor for pre-39
eclampsia.  40
41
KEY WORDS 42
Pre-eclampsia/ catechol-O-methyltransferase/ COMT/ Val158Met/ rs468043
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INTRODUCTION44
The pregnancy-associated complication pre-eclampsia is a leading cause of maternal 45
and fetal morbidity and mortality. Approximately 3% of all pregnant women in the 46
Western World are affected by pre-eclampsia (Saftlas et al., 1990), and in severe 47
cases the only effective treatment is delivery, irrespective of gestational age. The 48
classical clinical manifestations of pre-eclampsia are elevated blood pressure and 49
proteinuria. The etiology is complex and like other common complex disorders both 50
genetic and environmental factors influence the risk of developing the disease. 51
Genetic factors are suggested to be responsible for more than 50% of the liability to 52
pre-eclampsia (Moses et al., 2006, Salonen Ros et al., 2000), and several candidate 53
genes have been studied. However, the results are inconsistent and specific causative 54
genes involved in pre-eclampsia still remain to be identified.  55
56
A recent study put forward that deficiency in catechol-O-methyltransferase (COMT) 57
is associated with pre-eclampsia (Kanasaki et al., 2008). COMT is a key enzyme in 58
the degradation of both catecholamines and estrogens (Creveling, 2003). High- and 59
low-activity variants of COMT, due to single base changes, have been discovered 60
(Diatchenko et al., 2005). One polymorphism with functional implications is a non-61
synonymous G to A base change (rs4680; NM_000754.2), the COMT Val158Met62
polymorphism. The Met-allele of this polymorphism is associated with a three- to 63
four-fold decrease in COMT enzyme activity (Lotta et al., 1995), and several clinical 64
conditions such as pain perception (Diatchenko et al., 2005, Zubieta et al., 2003), 65
psychiatric disorders (Azzam and Mathews, 2003, Prasad et al., 2008, Woo et al.,66
2002), hypertension (Annerbrink et al., 2008, Hagen et al., 2007, Happonen et al.,67
Page 5 of 19
http://molehr.oxfordjournals.org/
Draft Manuscript Submitted to MHR for Peer Review
For
 R
eview
 O
nly
4
2006) and heart disease (Eriksson et al., 2004, Hagen et al., 2007, Voutilainen et al.,68
2007) have been reported to be associated with this single base change. 69
70
Inspired by Kanasaki et al.’s hypothesis that COMT deficiency is associated with pre-71
eclampsia we examined the potential role of the functional COMT Val158Met72
polymorphism in a large Norwegian case/control cohort. In addition, since the 73
maternal-fetal interface is a likely site for the abnormal mechanisms in the 74
pathogenesis of pre-eclampsia (Robertson et al., 1985) COMT gene expression in 75
decidual tissues from pre-eclamptic and normal pregnancies was also investigated. 76
77
MATERIALS AND METHODS 78
The HUNT population 79
All women subjected to genotyping were retrospectively identified from the second 80
Nord-Trøndelag Health Study (HUNT2) (Holmen et al., 2003). Pre-eclampsia was 81
defined as onset of persistent hypertension (exceeding 140/90 mmHg), in combination 82
with proteinuria (exceeding 300 mg/l per day) after 20 weeks gestation. Women with 83
pre-eclamptic and non-preeclamptic singleton pregnancies in the HUNT cohort were 84
identified by linking the HUNT database to the Medical Birth Registry of Norway 85
(MBRN) (Moses et al., 2008). The inhabitants of Nord-Trøndelag county are well 86
suited for genetic studies due to ethnic homogeneity (<3% non-Caucasians) (Holmen87
et al., 2003, Holmen et al., 2004). The HUNT population is described in detail 88
elsewhere (Moses et al., 2008). 89
90
Collection of decidual samples 91
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Human decidua basalis tissue was collected from Norwegian women, 13 with pre-92
eclampsia, 24 with both pre-eclampsia and small for gestational age (SGA) neonates 93
and 57 with normal pregnancies. Mean gestational age for cases was 32±4 weeks, and 94
39±1 weeks for controls. The tissue was obtained by vacuum aspiration of the 95
placental bed during cesarean section (Harsem et al., 2004, Staff et al., 1999) at St. 96
Olavs University Hospital and Haukeland University Hospital, Norway. Pre-97
eclampsia was defined as in the HUNT population, and SGA neonates were defined 98
as fetuses with a birth weight below the 10th percentile (Haram and Gjelland, 2007).99
100
SNP genotyping 101
DNA for genotyping was extracted from blood samples stored in the HUNT biobank, 102
as described elsewhere (Moses et al., 2008). An Applied Biosystems’ TaqMan 103
genotyping assay (Applied Biosystems, Foster City, U.S.A) was selected to genotype 104
the Val158Met (rs4680) SNP using 5 ng of genomic DNA from each of the 1,134 pre-105
eclamptic women and 2,263 control samples. This assay was performed on an 106
Applied Biosystems 7900HT Fast Real-Time PCR System and sample genotypes 107
were interrogated using the integrated 7900HT system data analysis software.108
109
Decidual transcriptional profiling 110
Total RNA was extracted from decidual tissues by a standard Trizol protocol 111
(Invitrogen, Carlsbad, U.S.A.), purified with Qiagen’s RNeasy Mini Kit (Qiagen, 112
Hilden, Germany) and evaluated on the Agilent Bioanalyzer 2100 (Agilent 113
Technologies, Waldbronn, Germany). Anti-sense RNA (aRNA) was synthesized, 114
purified with the Illumina TotalPrep RNA Amplification Kit (Ambion, Austin, 115
U.S.A.) and hybridized onto Illumina`s HumanWG-6 v2.0 Expression BeadChip®  116
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(Illumina, San Diego, U.S.A.). Hybridized aRNA samples were scanned on the 117
Illumina BeadStation 500GX BeadArray reader (Illumina, San Diego, U.S.A.) using 118
Illumina BeadScan image data acquisition software (version 3.5.49). Illumina’s 119
BeadStudio Gene Expression software module (version 3.2.7) was used to subtract 120
background noise signals and generate an output file for statistical analysis. 121
122
Statistical Analysis123
Statistical analyses of genotyping data were carried out in SPSS version 15 using a 124
Pearson’s Ȥ2 statistic. The decidual transcriptional profiles were pre-processed and 125
analyzed in the SOLAR statistical program (Almasy and Blangero, 1998) as 126
previously described in Göring et al. (Goring et al., 2007). To evaluate the magnitude 127
of differential expression for the COMT transcripts we measured the displacement of 128
the mean transcript levels between case and control groups by regressing on the case 129
group.130
131
Ethics132
The study was approved by the Regional Committee for Medical Research Ethics, the 133
National Data Inspectorate and The Directorate of Health and Social Welfare in 134
Norway. Ethical approval for total RNA processing and decidua expression analysis 135
was obtained from the Institutional Review Board at The University of Texas Health 136
Science Center in San Antonio.137
138
RESULTS139
COMT Val158Met genotyping and association analysis140
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Of the 1,134 pre-eclamptic cases and 2,263 controls, 1,100 cases (97.0%) and 2,188 141
controls (96.7%) were successfully genotyped. The Val158Met genotypes were 142
analyzed using both a dominant (GA+AA versus GG genotype frequency) and an 143
additive genetic model (G versus A allele frequency). We observed no association 144
between the COMT Val158Met polymorphism and pre-eclampsia in our Norwegian 145
cohort (dominant model p=0.93; additive model p=0.33) (Table 1). 146
147
COMT transcriptional profiling in decidual tissue148
The two COMT mRNA transcripts (NM_007310.1 and NM_000754.2) represented on 149
each expression array were significantly expressed in decidual tissue. However, 150
decidual expression levels for neither of the two COMT transcripts differed between 151
the case group (pre-eclampsia and pre-eclampsia+SGA) and the healthy controls 152
(p>0.7).153
154
DISCUSSION 155
COMT has recently been suggested to represent a novel pre-eclampsia susceptibility 156
gene (Kanasaki et al., 2008). Kanasaki et al. based their conclusion on the observation 157
that administration of 2-methoxyestradiol (2-ME), a natural metabolite of COMT, to 158
pregnant Comt-/- mice ameliorated pre-eclampsia-like symptoms. However, the 159
relevance of this mouse model for pre-eclampsia in humans has been a matter of 160
discussion (Banerjee et al., 2009), and based on this the present study was undertaken 161
to evaluate COMT as a candidate susceptibility gene in women. We observed no 162
association between the functional COMT Val158Met polymorphism and pre-163
eclampsia (Table 1). In addition, no differential expression of COMT transcripts in the 164
decidual tissues from pre-eclamptic women and controls was found. In accordance 165
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with our findings, COMT is not located in any of the regions previously shown to be 166
in significant linkage with pre-eclampsia susceptibility, contradicting the suggested 167
role of this gene as a maternal risk factor for pre-eclampsia (Arngrimsson et al., 1999, 168
Fitzpatrick et al., 2004, Johnson et al., 2007, Lachmeijer et al., 2001, Laivuori et al.,169
2003, Moses et al., 2000, Oudejans et al., 2004). On the other hand, studies have 170
reported association between COMT single nucleotide polymorphisms, e.g. 171
Val158Met, and blood pressure in humans (Annerbrink et al., 2008, Hagen et al.,172
2007, Happonen et al., 2006, Kamide et al., 2007), but such an association has not 173
been found in pregnancy-induced hypertension (Sun et al., 2004), suggesting that 174
mechanisms underlying hypertension in the pregnant and non-pregnant state may 175
differ. 176
177
The mouse model for pre-eclampsia used by Kanasaki et al. provides a link between 178
redox-regulated signaling and human pregnancy pathology (Kanasaki et al., 2008). 179
The COMT metabolite 2-ME acts like a pro-oxidant and has direct involvement in 180
redox-regulated signaling (Banerjee et al., 2009). Moreover, 2-ME degrades hypoxia 181
inducible factor-1 alpha (HIF-1Į) (Mooberry, 2003, Rimon et al., 2008), and since 182
HIF-1Į is essential in angiogenesis this activity may inhibit angiogenesis. Lack of 2-183
ME, as in the Comt-/- mice, may result in stable HIF-1Į and thus, increased oxidative 184
stress and vascular pathology. Due to absence of 2-ME in Comt-/- mice, the relevance 185
of this model for pre-eclampsia in humans has been questioned (Banerjee et al.,186
2009). Taken together with the additional potential role of HIF-1Į in inflammation 187
(Cramer et al., 2003) and lipopolysaccharide-induced sepsis (Peyssonnaux et al.,188
2007) it has been suggested that stable HIF-1Į alone at late pregnancy could elicit the 189
pre-eclampsia-like phenotypes in Comt-/- mice (Banerjee et al., 2009). Finally, it 190
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should be addressed that blood pressure regulation apparently differs in these mice 191
and humans. An association between COMT’ and blood pressure in non-pregnant 192
women has been revealed (Hagen et al., 2007). In contrast, blood pressure did not 193
differ between non-pregnant Comt-/- and wild type (Comt+/+) mice. 194
195
The COMT enzyme is reported to be active in both placenta (Barnea et al., 1988) and 196
decidua (Casey and MacDonald, 1983). In pre-eclamptic women reduced placental 197
COMT protein expression at term was observed in one study (Kanasaki et al., 2008), 198
and reduced placental COMT activity was detected in a second (Barnea et al., 1988). 199
However, both studies are small, 6 cases/6 controls and 10 cases/20 controls, 200
respectively. Levels of 2-ME vary throughout gestation, with extremely low levels 201
early in pregnancy and increasing levels towards term (Berg et al., 1983, Sugawara et 202
al., 2005). In one study reduced levels of circulating 2-ME was detected in pre-203
eclamptic pregnancies (8 cases/13 controls) (Kanasaki et al., 2008). When our COMT204
transcriptional profiling results in decidua basalis tissue, from a relatively large 205
number of pre-eclamptic and control women (37 and 57, respectively), are 206
inconsistent with the existing observations, we can only speculate about the cause of 207
these divergent observations. Possibilities include, different function of COMT in 208
placenta, which is of fetal origin, and decidua basalis, representing the maternal side, 209
the mRNA level does not correlate with protein levels, or the case groups of the 210
previous studies (Kanasaki et al., 2008, Barnea et al., 1988) are simply too small with 211
insufficient statistical power. 212
213
A few observations in humans suggest that placental COMT protein 214
expression/activity is altered in pre-eclampsia, but our COMT gene expression in 215
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decidua basalis tissue does not. Our highly powered case/control cohort study does 216
not support the hypothesis that an association between COMT/2-ME deficiency and 217
pre-eclampsia is due to variations in maternal COMT genotype. However, since only 218
one single polymorphism has been evaluated in the present study it may be too early 219
to draw final conclusions about the role of this enzyme in development of pre-220
eclampsia. 221
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2Abstract
Preeclampsia susceptibility demonstrates a complex pattern of inheritance. 
Epidemiological data suggest that both maternal and fetal genetic factors 
contribute to the risk of developing preeclampsia. Maternal susceptibility has 
previously been linked to chromosomes 2q, 5q and 13q in an Australian/New 
Zealand (Aust/NZ) familial cohort. In this present study, we aimed to investigate 
positional candidate SNP variations at the 13q locus in an extended set of Aust/NZ 
preeclampsia families and in a large Norwegian population-based case/control 
cohort (1 139 preeclampsia cases, 2 269 controls). Known coding and/or validated 
SNPs within several positional candidate genes were selected for genotyping in the 
two cohorts. Nominal significant evidence of association for an identical SNP in the 
tumor necrosis factor ligand superfamily member 13B (TNFSF13B) gene was 
detected in both the Aust/NZ and Norwegian cohorts (rs16972199; p=0.015 and 
p=0.017, respectively). Subsequently, a combined cohort association analysis was 
performed providing greater evidence for association with preeclampsia 
susceptibility (p=0.002). This combined cohort association result remained 
significant after correcting for the total experiment (p=0.047). TNFSF13B 
influences the immune response and has previously been ascribed an important 
role in the development of preeclampsia by affecting the normal maternal-fetal 
immune adaptation. This physiological evidence emphasizes the importance of our 
genetic findings whereby we propose TNFSF13B as a novel maternal preeclampsia 
susceptibility gene.
Introduction
3Preeclampsia is a pregnancy-associated complication with substantial maternal and fetal 
morbidity and mortality. The incidence of preeclampsia is estimated to range from 2-
5%,1 although this rate is higher in developing countries2 and amongst certain ethnic 
groups.3 A complete understanding of the etiology and pathogenesis of the preeclampsia 
syndrome remains elusive. Whilst the clinical gestational hypertensive and proteinuric 
manifestations usually present themselves after 20 weeks gestation, the mechanisms 
underlying these manifestations are likely to occur at a much earlier gestational age. 
This dichotomy of pathophysiological events has therefore been proposed to represent a 
two-stage process, with poor placental perfusion (stage 1) leading to the maternal 
responses evoked with varying degrees of clinical manifestations (stage 2).4 This model 
has recently been modified,5 based on the hypothesis that abnormal 
implantation/placentation occurs before abnormal vascular remodeling of spiral 
arteries.6 In addition, it is suggested that maternal constitutional factors (genetic, 
behavioral or environmental) may play a more extensive role than previously thought 
and that several factors, which may differ in different women, may serve as linkers 
between the two stages.5
An intriguing aspect of normal pregnancy is the maternal host’s “acceptance” of 
paternal antigens derived from the fetal allograft, which presents a genetically distinct 
set of human leukocyte antigens (HLAs; HLA-C, -E and -G). In a preeclamptic 
pregnancy however, this “acceptance” is thought to be perturbed in a manner akin to the 
immunological dynamics as seen in organ graft rejection 7. The proposed maternal-fetal 
immune maladaption has been ascribed to a disturbed interaction between maternal 
immune cells (natural killer (NK) cells) and invading trophoblasts. At the 
4epidemiological level, immune maladaptation may be involved due to an increased risk 
of preeclampsia seen in primiparous women,8 women receiving donor insemination,9-11
women having only a short period of sexual cohabitation with their partners before 
conception and in multiparous women after changing partners (primipaternity)12-14.
It is well documented that preeclampsia is a complex disorder with both genetic and 
environmental factors attributing to a susceptibility continuum for developing the 
disease.15 However, like the majority of other common complex diseases, the mode of 
preeclampsia inheritance is unclear. Positional cloning efforts have been initiated in 
attempts to identify the genetic risk factors. By examining the probability of co-
segregating loci within a familial cohort, several loci most likely to harbor maternal 
susceptibility genes have been identified (reviewed in 16-18). Linkage studies in an 
Australian/New Zealand (Aust/NZ) familial cohort initially identified a maternal 
preeclampsia susceptibility locus to chromosome 2q.19,20 The Aust/NZ genome-wide 
linkage scan data set has been re-analyzed under the assumption that the underlying 
liability of preeclampsia is inherently quantitative, implying that any preeclampsia 
susceptibility gene will represent a quantitative trait locus (QTL). Such an approach 
allows a more refined variance-components-based procedure utilizing a biological 
threshold model for the preeclampsia phenotype. Application of this efficient genetic 
linkage analysis method to the original Aust/NZ genome-wide linkage scan data set 19,20
resolved and the strengthened the chromosome 2 linkage signal to 2q22.21 In addition, 
two novel maternal preeclampsia susceptibility QTLs to chromosomes 5q and 13q were 
revealed.22
5In our efforts to identify the susceptibility gene(s) at the 2q22 QTL, we have utilized an 
extended Aust/NZ familial cohort and an independent retrospective Norwegian 
case/control cohort. Association to the activin A receptor, type IIA (ACVR2A) gene on 
2q22 was found.23,24 We now report on our efforts to identify the susceptibility gene(s) 
at the 13q QTL. Several plausible genes were interrogated with a genetic association 
identified for a concordant SNP in the tumor necrosis factor (ligand) superfamily 13B 
(TNFSF13B) gene and preeclampsia susceptibility. The independent confirmation of a 
TNFSF13B SNP is a novel finding and a possible role for this gene in preeclampsia 
pathogenesis is discussed.
Materials and method 
Australian study population 
The Aust/NZ familial cohort consists of the original set of 34 (26 Australian and eight 
New Zealand) families that we have previously used to localize the 2q, 5q and 13q 
preeclampsia susceptibility QTLs19-22 and an additional 40 (Australian) preeclampsia 
families that we have subsequently ascertained and recently described.23 The original 34 
families are herein called “The 34 Family Cohort”, the entire familial sample is herein 
called “The 74 Family Cohort” and all family members are of Caucasian origin. 
Norwegian study population 
All women in the Norwegian cohort were retrospectively identified from Nord-
Trøndelag County in Norway as part of a large multipurpose health survey conducted 
during 1995-1997 (the HUNT2 study). More than 65 000 inhabitants participated. The 
people living in Nord-Trøndelag County are considered representative of the Norwegian 
6population, and are well suited for genetic studies because of ethnic homogeneity (<3% 
non-Caucasians).25,26 The study population is described in detail elsewhere.27
Preeclampsia diagnosis 
Preeclampsia diagnosis in the Australian and Norwegian cohorts was based on the 
development of hypertension and an elevation of protein levels in the urine during 
pregnancy. Multiple blood pressure readings and a quantitative (24 hour urine sample) 
or qualitative (random proteinuria dipstick reading) test were performed. 
Australia/New Zealand
Preeclampsia diagnosis was performed by qualified clinicians, using criteria set by the 
Australasian Society for the Study of Hypertension in Pregnancy.28,29 Pregnant women 
were considered preeclamptic if they, on at least two occasions six or more hours apart, 
had (1) a rise from baseline systolic blood pressure (SBP) of at least 25mmHg and/or a 
rise from baseline diastolic blood pressure (DBP) of at least 15mmHg; or (2) SBP 
t140mmHg, and/or DBP t90mmHg. Additionally, proteinuric levels were >0.3 g/L in a 
24 hour specimen or at least a +2 proteinuria dipstick reading from a random urine 
collection. Women who satisfied these criteria and experienced convulsions or 
unconsciousness in their perinatal period were diagnosed as having eclampsia. Women 
with pre-existing hypertension or other medical conditions known to predispose for 
preeclampsia (e.g., renal disease, diabetes, twin pregnancies or fetal chromosomal 
abnormalities) were excluded. Under these criteria, The 74 Family Cohort (n=480) 
included 140 women coded as affected (20 with eclampsia, 120 with preeclampsia) and 
90 women coded as unaffected (normotensive and non-proteinuric).  
7Norway
Preeclampsia in the Norwegian case/control cohort was defined using the criteria given 
by National High Blood Pressure Education Program Working Group on High Blood 
Pressure in Pregnancy.30 Preeclampsia was defined as the onset of persistent 
hypertension (blood pressure 140/90 mmHg), in combination with proteinuria (0.3
g/L in a 24 hour urine sample or 1+ on urine dipstick) after the 20th week of gestation. 
Preeclamptic women and women who had normal pregnancies in the HUNT cohort 
were identified by linking the HUNT database to the database at the Medical Birth 
Registry of Norway (MBRN) described in more detail elsewhere.27 Clinical information 
of all deliveries in Norway has been sent to MBRN since 1967. We identified 1 139 
women registered with preeclampsia (cases) and 2 269 women with a history of normal 
pregnancies as controls, with blood samples available at the HUNT biobank.  
Positional candidate SNP selection 
Publicly available sequence SNPs were selected from the NCBI SNP database (Homo 
sapiens dbSNP build 125, http://www.ncbi.nlm.nih.gov/SNP/).
SNP genotyping in the Aust/NZ cohort 
Extraction of genomic DNA from peripheral blood samples has been previously 
described.20 SNP typing in The 74 Family Cohort was performed with Illumina’s 
GoldenGate SNP Genotyping Assay (Illumina Inc., San Diego, CA). The design of 
two allele specific oligos and one locus specific oligo in conjunction with a universal set 
of amplification primers applied to a bead array substrate makes the GoldenGate assay 
8highly robust and specific in a large multiplex reaction. A custom SNP pool was 
designed using Illumina’s Assay Design Tool and sample genotyping was performed 
using Illumina’s 8u12 Sentrix Array Matrix (SAM). Each SAM was imaged on the 
Illumina BeadStation 500GX BeadArray Reader using Illumina BeadScan image data 
acquisition software (version 2.3.0.13). SNP genotype clustering and individual sample 
genotype calls were interrogated using the Illumina BeadStudio software, Genotyping 
Module (version 2.3.41). 
SNP genotyping in the Norwegian cohort  
DNA for genotyping was extracted from peripheral blood samples stored in the HUNT 
biobank as described elsewhere.24,27 The Applied Biosystems SNPlexTM Genotyping 
System (Applied Biosystems, Foster City, CA) was employed for SNP genotyping. All 
samples were electrophoretically separated on a 3730 DNA Genetic Analyzer (Applied 
Biosystems), and automated allele calls and genotype clustering of each individual 
sample was performed using Applied Biosystems’ GeneMapper® Software (version 4.0) 
as previously described.24,27
Statistical methods 
SNP allele frequency estimation
We used the statistical genetics analysis program SOLAR to estimate SNP allele 
frequencies by using maximum likelihood techniques that account for pedigree 
structure.31 Tests for deviations from Hardy-Weinberg equilibrium (HWE) were also 
performed in SOLAR. 
9Intra- and inter-genic SNP linkage disequilibrium estimates
Estimates of pairwise linkage disequilibria parameters amongst intra-genic SNPs were 
used in a basic correlation method to assess all disequilibria jointly in SOLAR. In this 
approach, SNP genotypes are scored as -1, 0 and 1 (for the AA, AB and BB genotypes, 
respectively) and the correlations among these data vectors are calculated to give an 
unbiased estimate of the squared LD correlation, rho (U).
SNP association analysis
The SNP association analyses were conducted using SOLAR’s QTLD procedure.32 This 
procedure performs a test for population stratification and two commonly used 
association tests: the quantitative transmission disequilibrium test (QTDT),33 and the 
measured genotype test.34 The QTDT procedure as described by Abecasis et al.33 is not 
limited to the scoring of allele transmission from parents to offspring but extends further 
to assess the entire pedigree structure. The scoring of allele transmission can be 
performed for quantitative or qualitative traits and it has been modified in SOLAR to 
work with discrete traits using a threshold model.35 The QTDT statistic is used to report 
association results for the Aust/NZ familial cohort. The measured genotype analysis 
uses a standard threshold model assuming an underlying normal distribution of liability. 
The threshold model and its assumptions are near identical to those used in standard 
logistic regression but benefits from the ease of interpretation with regard to genetic 
effects. The measured genotype test of associations can assess the extent of genotypic 
mean differences (or the liability or risk scale) between case and control singletons 
assuming a model of additive gene action.34 The measured genotype test is used to 
report statistical results for the Norwegian case/control cohort. To accommodate for 
10
multiple hypothesis testing, we used the approach of Li and Ji36 to determine the 
effective number of independent SNPs (and tests). This algorithmic approach has been 
implemented into SOLAR and it evaluates the strength of correlation amongst the 
observed genotypes at each SNP locus within a gene. 
Combined cohort analysis
To analyze concordant results in both the Aust/NZ and Norwegian cohorts we used 
Fisher’s combined probability test.37 Fisher’s combined probability test uses the 
independent p-values (pi) from y tests to calculate the test statistic  i
y
i
y pln2
1
2
2 ¦
 
 F
with 2y degrees of freedom for the combined cohorts. With this approach we evaluate 
the same null hypothesis; positional candidate SNPs are not associated with 
preeclampsia genetic susceptibility, in both cohorts. 
Ethics
Australia
Ethical approval for the recruitment of Aust/NZ preeclampsia family members was 
granted by the Royal Women’s Hospital Research and Ethics Committees, Melbourne, 
Australia. Written informed consent was obtained from study participants prior to them 
being phlebotomized. Ethical approval for the quantitative genetic analysis of The 34 
Family Cohort plus molecular genetic investigation across the 13q QTL in The 74 
Family Cohort was obtained from The University of Texas Health Science Center at 
San Antonio, Institutional Review Board. 
Norway
11
Prior approval to use the Norwegian case/control cohort for genetic studies was 
obtained by the Regional Committee for Medical Research Ethics, Norway and 
approved by the National Data Inspectorate and The Directorate of Health and Social 
Welfare. Ethical approval for genotyping and statistical analysis of the Norwegian 
case/control cohort was obtained from The University of Texas Health Science Center 
at San Antonio, Institutional Review Board. 
Results
Positional Candidate SNP Selection 
We interrogated the 3-LOD drop (99% confidence) interval at the Australian 13q QTL 
to prioritize positional candidate genes for further study. The interrogated region 
extended from D13S158 (98.96 cM) to D13S285 (123.78 cM). Based on relevance to 
current and emerging concepts of the pathophysiology of preeclampsia, the tumor 
necrosis factor (ligand) superfamily 13B (TNFSF13B), ephrin-B2 (EFNB2) and the 
coagulation factor VII (F7) and X (F10) genes were selected for further study. The 
TNFSF13B and EFNB2 genes were selected because of their emerging role in placental 
development and function.38-43 The F7 and F10 genes were considered to be plausible 
biological candidates given the known relationship between maternal thrombophilias 
and an elevated risk of developing preeclampsia.44
From the four prioritized genes we selected 24 validated sequence SNPs from NCBI’s 
SNP database (Homo sapiens dbSNP build 125) for genotyping in the Aust/NZ and 
Norwegian cohorts (Table 1). Coding SNPs representing variants likely to be functional 
and SNPs in gene regulatory regions (i.e. the proximal promoter and the 5’ and 3’ 
12
untranslated regions), were given high priority. In order to provide sufficient coverage 
across the TNFSF13B gene we also selected validated intronic SNPs at ~6 kb intervals.
SNP genotyping and association analysis in the Aust/NZ cohort 
All 24 SNPs were successfully designed into an Illumina custom SNP pool (Table 1). In 
the Aust/NZ cohort one SNP failed the genotyping assay and 11 SNPs were non-
polymorphic (Table 1). In order to effectively analyze SNP genotype data, these and an 
additional SNP (with very low copy number of the minor allele, n<5) were subsequently 
omitted from all statistical analyses. For the 11 remaining SNPs genotyped in the 
Aust/NZ cohort we observed a very high individual sample genotyping success rate 
(t98.3%), and all SNPs conformed to Hardy-Weinberg expectations (HWE) (p>0.05). 
Based on the prior assumption that the underlying liability of preeclampsia is inherently 
quantitative, and therefore any preeclampsia gene represents a QTL,21,22 we have 
independently analyzed the four 13q QTL candidate genes. 
The TNFSF13B gene presented a nominal association for the rs16972199 SNP with 
preeclampsia (p=0.015) in the Aust/NZ cohort (Table 1). The evaluation of intra-genic 
SNP dependence in this gene for the Aust/NZ cohort reports an adjusted p-value of 
0.013 based on the six genotyped SNPs effectively representing 3.7 independent tests 
(Figure 1a). None of the tested SNPs in the remaining three genes (EFNB2, F7 and F10)
were associated with preeclampsia in the Aust/NZ cohort (p>0.05) (Table 1). 
SNP genotyping and association analysis in the Norwegian cohort 
13
In the Norwegian cohort two SNPs failed the Applied Biosystems SNPlex assay design, 
one SNP could not be successfully genotyped and 10 SNPs were non-polymorphic 
(Table 2). In order to effectively analyze SNP genotype data, these and an additional 
two SNPs (with very low copy number of the minor allele, n<5) were subsequently 
omitted from all statistical analyses (Table 1). Of the remaining nine SNPs genotyped in 
the Norwegian cohort we observed a moderate individual sample genotyping success 
rate (mean=77%; range 60.3-82.1%) and all SNPs conformed to HWE (p>0.05). 
In the Norwegian cohort the TNFSF13B gene also presented a nominal association for 
rs16972199 (p=0.017) with preeclampsia (Table 1). The evaluation of intra-genic SNP 
dependence in the TNFSF13B gene for the Norwegian cohort revealed an adjusted p-
value of 0.015 based on the five genotyped SNPs effectively representing 3.3 
independent tests (Figure 1b). None of the tested SNPs in the remaining three genes 
(EFNB2, F7 and F10) were associated with preeclampsia in the Norwegian cohort 
(p>0.05) (Table 1). 
TNFSF13B SNP association confirmed in the combined Aust/NZ and Norwegian 
cohorts
We used a Fisher’s combined probability test37 to analyze the combined rs16972199 
association data from the Aust/NZ and Norwegian cohorts. This analysis generated a 
significant association with preeclampsia susceptibility (F2=16.569; p=0.002). To 
correct our combined rs16972199 p-value at an experiment-wide level we first 
independently generated experiment-wide p-values for the Aust/NZ and Norwegian 
cohorts. In the Aust/NZ cohort we used SOLAR31 to simulate a quantitative trait with a 
14
heritability of 0.5121 and assigned affection status to a fixed number of affected women 
with the highest simulated trait values. The number of affected women was determined 
from The 74 Family Cohort (n=140 women with preeclampsia). The QTDT was 
repeated 10 000 times to our simulated trait resulting in an experiment-wide p-value of 
0.1009 for rs16972199 in the Aust/NZ cohort. Permutation analyses (n=10 000) for 
rs16972199 in the Norwegian cohort generated an experiment-wide p-value of 0.0815. 
The combined, experiment-wide analysis of rs16972199 in the Aust/NZ and Norwegian 
cohorts confirms a significant association of this SNP with preeclampsia genetic 
susceptibility (F2=9.601; p=0.047). 
Discussion
The elucidation of genetic risk for developing preeclampsia is a major challenge in 
obstetric medicine. More than 50 candidate genes have been considered, with the 
majority of studies being underpowered and providing weak associations that fail to 
replicate in different population samples.18,45 We have adopted the positional cloning 
approach, initially performing linkage analysis in affected families to localize the 
chromosomal regions most likely to harbor genetic risk factors. Having identified 
susceptibility loci on chromosomes 2q, 5q and 13q we are now in a position to focus our 
efforts on plausible positional candidate genes. In this current study, significant 
association between a single SNP (rs16972199) within the TNFSF13B gene and 
preeclampsia susceptibility was found in independent population samples from 
Australian/New Zealand and Norway. The TNFSF13B gene belongs to the TNF 
superfamily of genes that play important roles in the immune response. TNFSF13B 
plays an important role in adaptive immune responses,46,47 potentially regulating the 
15
function of innate immune cells.48 Recent reports indicate that both placental 
trophoblast cells and maternal decidual cells express TNFSF13B.40,49 The observed 
association between TNFSF13B and preeclampsia in this study suggests that the 
influence of the maternal immune system is significant and may be consistent with the 
theory that maternal-fetal immune maladaption is central in the pathogenesis of the 
syndrome.  
TNFSF13B, also known as BAFF, BLYS, TALL-1, zTNF4, THANK, CD257, 
TNFSF20 and DTL, is a member of the TNF superfamily. In general, ligands and 
receptors of the TNF superfamily are involved in cell signaling pathways within basic 
processes such as development/differentiation, cell survival/death and host defense.50 A 
vital role has been ascribed to TNFSF13B in the adaptive immune system (B-
lymphocyte stimulator), but recently, it has been documented that TNFSF13B also 
regulates function of innate immune cells.48 More specific, TNFSF13B stimulates 
monocyte survival and induces activation and differentiation into macrophage-like 
cells.48 It is well known that NK cells have a major role in human reproduction.51 NK 
cells are suggested to provide benefit by secreting a number of cytokines, chemokines 
and angiogenic factors rather than to exert a cytotoxic activity,52 and the interaction 
between decidual NK cells and the allogenic extravillous trophoblast (EVT) cells has 
been suggested to contribute to the depth of EVT cell invasion during 
implantation/placentation.53 An inadequate, shallow EVT cell invasion is a precursor to 
insufficient decidual spiral artery remodeling leading to ischemic, oxidative stress 
responses because of reduced placental perfusion and by this, the pathogenesis of 
preeclampsia may be initiated. NK cell activity has been shown to be elevated by 
16
TNFSF13B in mice,54,55 but so far, it is not known if or how the TNFSF13B protein 
influences the human NK cell response in vivo. 
During implantation, the accumulation of NK cells in decidua is probably based on 
recruitment from maternal circulation.56 Maternal decidual stromal cells (DSCs) are 
apparently central in this NK cell recruitment.56 DSCs constitute the main cellular
component of the decidua, and they are involved in a number of different immune 
functions that are important for the immunological cross-talk between the mother and 
the fetus, with consequences for pregnancy outcome.57-61 Recently, DSCs have been 
shown to express TNFSF13B mRNA and protein,49 implying that our finding of an 
association between TNFSF13B and preeclampsia may reflect an abnormal 
immunological function of DSCs at the maternal-fetal interface.  
The establishment of an intrauterine immune privileged site for the fetus is essential for 
successful pregnancy and the invading fetal trophoblasts have been assigned a major 
role in this process.62 Among the factors expressed by trophoblasts known to confer 
immune privilege are the death-inducing members of the TNF superfamily ligands.38,63-
67 The non-apoptosis-inducing TNFSF13B has also been suggested to play a role in cell 
differentiation and placental development/function.38-40 Both TNFSF13B gene and 
protein are expressed by cytotrophoblasts.40,49 A potential role in angiogenesis has also 
been suggested based on the observation that TNFSF13B is detected in blood vessel 
endothelium of normal pregnant women, being absent in abortion patients.49
Angiogenesis is essential for normal placental development, and abnormal angiogenesis 
with insufficient remodeling of spiral arteries is a hallmark of preeclampsia. 
17
Furthermore, in normal early pregnancy, a prominent expression of TNFSF13B has 
been detected in trophoblasts and deciduas, with decreased levels in tissues from 
women with recurrent spontaneous abortions.49 It has been suggested that trophoblast 
TNFSF13B may navigate maternal leukocytes toward a maternal immune response, 
being beneficial for the fetus, instead of a harmful one.49  If so, fetal TNFSF13B alone
or in combination with maternal genotype, may influence preeclampsia development. 
However, addressing this question was outside the scope of the present investigation. 
The TNFSF13B rs16972199 SNP showing association with preeclampsia in this study is 
a rare intronic SNP for which there is no obvious functional consequence. The 
functional evaluation of SNPs in putative gene regulatory regions (including intronic 
sequences) is particularly challenging and becoming more important as the pace of 
discovery in complex disease genetics increases.68 Recent examples include association 
between intronic SNPs and breast cancer,69,70 systemic  lupus erythematosus (SLE),71
lumbal-disc herniation (LDH),72 Crohn’s disease,73 schizophrenia,74 asthma75 and 
dyslipidemia76. At this stage however, we cannot rule out the possibility that there exists 
other as yet unidentified rare sequence variant(s) in linkage disequilibrium (LD) with 
the rs16972199 SNP that are the actual causal mutations. Deep re-sequencing in and 
around the TNFSF13B gene in our preeclampsia cohorts will be required to enumerate 
and prioritize all variation prior to formal functional evaluation. 
In conclusion, the finding of genetic association between the TNFSF13B SNP and 
maternal preeclampsia susceptibility in two independent populations strongly implicates 
this gene as a novel preeclampsia susceptibility gene, and supports the hypothesis that 
18
this gene may be of profound importance for a variety of processes essential to a 
successful human pregnancy. Moreover, TNFSF13B might be a potential factor 
bridging the angiogenic and non-cytotoxic response machineries at the maternal-fetal 
interface.
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Titles and legends to figures 
Figure 1. The pattern of linkage disequilibrium (LD) for successfully genotyped 
TNFSF13B SNPs in (a) the Aust/NZ family cohort and (b) the Norwegian 
case/control cohort. LD is measured by the squared value of the pairwise 
correlation amongst intra-genic genotypes (U2) and the strength of correlation is 
depicted in the colored bar to the right of the LD plot. The intensity of red colour 
in a block increases with the strength of SNP allele correlation from white (0) 
indicating no correlation (i.e. LD) to red (1.0) indicating a perfect correlation (i.e. 
complete LD).
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